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P, l-H.S.A., Se-selenomethionine, Hg-ch]ormerodrin,
^7Ga-citrate and labelled bleomycin compounds are discussed in a historical
review. There are similarities in the tumours demonstrable by these agents
and all of them may be taken up into inflammatory exudates, suggesting that,
while differences in the metabolism of each agent exist, their mechanism
of uptake may be predominantly non-specific.
Clinical studies have led to the following conclusions:
1). 67Ga -citrate is a more useful tumour imaging agent than ^^In-b1eomycin,
for lesions above the diaphragm.
2). ^7Ga-citrate scanning is useful in the management of seminoma of the
testis, giving consistently accurate tumour localization. Scans in patients
with teratoma of the testis were less consistently positive. In patients
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dominant tumour type at the time of scanning.
673). A retrospective analysis of 'Ga-citrate scans in patients with
Hodgkin's Disease suggested that patients with lesions exhibiting high
£ 7
levels of Ga uptake may have a more aggressive form of disease or may be
in a more aggressive phase of their disease than pat i efits "wi th a low level
of uptake; a prospective study is required for confirmation.
G~7
The mechanism of uptake of Ga into tissues is discussed and was
studied in several experiments. Comparative studies of the uptake of ^~Ga
h5
and Ca in iactating and tumour-bearing dogs have shown that while there
may be similarities in the metabolic pathways of gallium and calcium in the
I
lactating mammary gland, there is no similarity in the mechanism of
uptake of these two elements into tumours.
Experiments using transplantable rodent tumours with variable
percentages of tumour macrophages suggested that macrophages per se do
not play a major role in ^Ga uptake.
* 6 7 125
A preliminary study of Ga and ''l-labelled serum albumin
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la). AIMS OF RADIOPHARMACEUTICAL TUMOUR IMAGING
In order to improve the treatment of malignant disease by surgery,
radiotherapy or chemotherapy, we must necessarily devise more sensitive
techniques to increase our diagnostic accuracy. The importance of a thorough
and accurate pre-treatment staging work-up for patients with malignant disease
is now widely accepted, and this can only result in more appropriate therapy
for patients.
The development of a reasonably safe radioactive scanning agent
localizing in malignant neoplasms in high concentration enabling a reliable
and accurate mapping of the primary tumour, its local spread and distant
metastases would be a very great advance in the management of malignant disease.
If this agent were sufficiently specific for malignant neoplasms then a very
useful aid to differential diagnosis would be available to us.
A>t the d resent time, however; red inert Ivp substances which localize
within tumours play only a limited role in the management of the cancer
patient. This is because of the generally low tumour:background ratios achieved
by currently available agents.
When a radiopharmaceutical is called "a tumour scanning agent" or
a "tumour localizing agent" this implies not merely that the agent concentrates
within a tumour but that it concentrates to a sufficient extent to enable a
clinically useful scan to be produced using currently available instruments.
We now have reached the stage when gamma-imaging instruments are extremely
e-ffective and further improvement in instrumentation is unlikely to offer
much in the way of increasing our diagnostic efficiency. It is the concentration
ratio of tumour:background tissue which determines whether or not a lesion can
3
be detected by radiopharmaceuticals. Typically when a tumourrbackgrourid tissue
ratio is 2:1, even a superficial lesion must be of the order of 2 cm. in
diameter before it wi11 be detected. Obviously, improvement of the concentration
ratio of the agent will enable smaller lesions to be seen.
1b). EARLY TUMOUR IMAGING AGENTS
Even before the development of the high energy photon scintillation
scanners in the late forties and early fifties, the idea of tumour localization
by means of radioisotopes had received some attention. By and large, the
techniques involved Geiger-Muel1er counters used as probe detectors. When
32
P was introduced in 1936 and found to be effective in the treatment of the
myeloproliferative disorders, much interest naturally arose as to its possible
therapeutic effect in other neoplastic conditions. Disappointingly, the
affinity of radioactive phosphorus for other types of malignancy was low-
except for brain tumours (Erickson, Larson and Gordon, 19^8), but the
concentrations achieved in the brain were of the'same order as those occurring
in other tissues with a rapid rate of phosphate metabolism such as the liver,
and therefore, emphasis fell less on its therapeutic use in the brain and
more on its diagnostic use as a tumour localizing agent. It found a limited
clinical application in determining the extent of a brain tumour at operation
(Stapleton, McKissock and Farran, 1952).
131
Similarly I may be said to be an early tumour localizing agent.
Known to localize in certain functioning thyroid carcinomas, particularly
131follicular carcinoma of the thyroid, I was first used in the forties for
the treatment of inoperable functioning carcinomas. The main problem was
whether or riot the tumour would take up the rad io- i sotope. Thus, often
k
131
these patients were given a tracer dose of i, again detected by Geiger-
Mueller counters (Pochin, 1956).
1c). GAMMA-EMiTTING RAD IOPHARMACEUTt CALS
Further advances in tumour localization using radio-isotopes had
to await the development of high energy scintillation detectors. These became
generally available in the early fifties but for a number of years tumour
131
delineation was limited to the uptake of I functioning thyroid tumours, the
outlining of brain tumours and the demonstration of filling defects in certain
organs using various radio-active compounds.
1• RAD IOMERCURY COMPOUNDS
203In 1960, Hg-chlornierodrin was introduced as a brain scanning
i 97
agent. Later, " Hg-cnlormerodrin was produced for brain scanning .purposes
and was a safer agent because of a much lower radiation dose to the kidneys.
Curiously, it was not until four years later that Sodee, Renner and Di Stefano
(1966) noticed that this agent concentrated in malignant tissues. Thev
reported an impressive success rate particularly in malignant tumours of the
lung, eye, nasopharynx, and in the lymphomas. Uptake was also present in a
high percentage of patients with tumours of the pancreas, bowel, bone and
breast although fewer cases of these were scanned. Interestingly, several
false positives were encountered in the group of lung lesions and these
eventually turned out to be cases of histoplasmosis and tuberculosis, causes
197 197of uptake which are not limited to Hg-chlormerodrin or Hg CI^-
Subsequently many papers have appeared, particularly from France,
197 197
reporting series of patients tested with Hg-chlormerodr in or Hg
showing that good scans can be obtained in a variety of neoplasms (Rosenthal!,
Greyson, and Eidinger, 1970; Lamy et al., 1970). Indeed in many aspects the
range of tumours having favourable uptakes are comparable to those obtained
with ^'Ga-c i trate, probably the most widely used of tumour scanning agents
(see Table 1 p 6). Carcinoma of bronchus, secondary lung metastases and
lymphomas generally show good uptake of radio-mercury compounds. For
example, in carcinoma of the bronchus, of 217 cases reported in the world
literature, 81% had positive scans, compared with 89% of 308 cases using
& 7
Ga-citrate. Again of interest in these papers is the incorporation of
197
Hg C1^ into various benign lesions which closely parallels the behaviour
/ 7
of Ga-citrate. In a proportion of cases of sarcoidosis, abestosis, lung
197
abscess, bacterial pneumonias and tuberculosis, uptake of Hg Cl^ occurs.
The cases of sarcoidosis showing uptake are those patients with active
disease, particularly if hilar lymph node involvement is present. In general,
the chronic sarcoidosis patient with fibrosis has a negative scan. Issac
et al., (1970) showed uptake in active tuberculosis but not in chronic
tuberculosis. Bacterial pneumonias may also show uptake. These are all
fa ~]
lesions which exhibit Ga-citrate uptake.
The mechanism of uptake of radio-mercury compounds is unknown but
very little research has been done on the subject. Biopsies from two cases
of astrocytomas have been investigated using autoradiography, and accumulation
of radioactivity was seen to occur on or within the neoplastic cells (Jackson,
Carson and Dick 19&7).
One serious disadvantage of radio-mercury compounds is the radiation
197dose to the kidneys. Even in the case of Hg, this may amount to 5~13 rads
when 10 Ci/kg body weight is administered.
TABLE I













20/30 (1) 36/54 (13)
Hodgkin's disease 100% 82%








163/203 (9) 276/308 (12)
Mesothelioma 40% 60%
2/5 (1) 3/5 (3)
Carcinoid tumour








However, more fundamentally, although these radio-mercury compounds
and 'Ga-citrate appear to be taken up by the same kinds of lesions, the
quality of scans obtained, reflecting the relative concentration of the agent
within the tumour and the tissue background, is higher with ^Ga-citrate than
197with Hg-chlormerodrin or chloride, although no comparative clinical trials
have been carried out.
2• 131 I~LABELLED COMPOUNDS
It is known that malignant tumours in experimental rats and mice
take up larger amounts of unaltered plasma proteins from the circulation
than do other tissues (Mego and McQueen, 1965). It is reasonable to expect
that the same phenomenon may exist in man. What is known is that certain radio-
iodinated protein compounds do localize in human malignant tumours and can be
detected in sufficient concentration to produce reasonable scans. The compound
131 131
most widely used in man has been l-labelled human serum albumin. ' I-
131
labelled fibrinogen (Day, Pianisek and Pressman, 1959) and J l-labelled
globulin (Hiramatsu et al., 1965) have been used in experimental animals in
131
addition to l-labelled album:,n. Finney and his co-workers (196^+) reported
131that l-labelled albumin concentrated in the Walker 256 carcinoma in rats
and the VX2 carcinoma in rabbits, but felt that tnis occurred only after intra¬
arterial perfusion of the tumour with hydrogen peroxide. The same group also
131studied I H.S.A. uptake in human cancers and reported favourable concentration
after perfusion, but poor concentration if peroxide was not perfused. Details
of the controls used were not given in their paper, and shortly after it
was shown that neither hydrogen peroxide nor intra-arterial administration
1 O 1
seemed to be necessary for uptake of I H.S.A, to occur. Bonte el al., (1966)
and Hisada, Hirakl and Ohba (1966) have both reported series of patients scanned
131
using ! H.S.A. given intravenously. These scans are often of good quality
and interestingly, there is a high success rate in gynecological cancers. This
t ~j
is a tumour type which has a disappointing success rate using Ga-citrate and
suggests more fundamental difference in the behaviour of the two agents towards
gynecological tumours (see table 2). Bonte et al., (1366) have discussed the
131
mode of uptake of I H.S.A. based on work done on experimental rabbits using
the V2 carcinoma and on studies of patients suffering from malignant disease.
131
He suggested that the I H.S.A. rapidly dispersed evenly throughout the blood
pool of the tumour and normal structures. After 2k hours, secondary mechanisms
131
come into play. There is a pooling of I H.S.A. within the necrotic centre
of a rapidly growing tumour. Since malignant cells have the property of
pinocytosis of proteins, this may well account for the presence of the radio¬
isotope on or within the neoplastic cell. The same group also suggested that
concentrations of tumour scanning agents might be improved by giving substances
capable of increasing the permeability of the blood vessels of the tumour. The
leakage of plasma proteins may also account for the positive scans seen in the
cases of inflammatory and granulomatous exudate.
Fibrin is laid down around malignant tumours and especially rapidly
131 131
growing ones. This had lead to the use of l-labelled fibrinogen and I-
labelled anti-fibrin antibodies in experimental animals. There is certainly
sufficient concentration of the compounds in the region of tumours to obtain
scans. In some tumours, high tumour:background ratios are achieved but only
limited trials have been conducted on patients (Day et al., 1959).
It might be worth looking at these compounds again from the point
of view of scanning malignancies from the female reproductive tract.
9
3 . ' 75SELENIUH COMPOUNDS
75Selenium labelled compounds have been used since the mid-sixties
for the demonstration of certain tumours using the technique of whole body
scanning, although following the introduction of ^Ga-citrate in 1969, their
use for this purpose has diminished considerably. They remain, however, an
interesting group of compounds since reported clinical and experimental studies
of their uptake into tumours provided a comparison to studies of the uptake
mechanisms of the more recently introduced tumour imaging agents.
The first ^Selenium compound to be used for tumour detection was
^Se-selen i te. Its introduction for this purpose was initially based on the
hypothesis that because of similarities in the chemical properties of selenium
and sulphur, tumours which laid down chondroitin sulphate (i.e. cartilaginous
tumours) minht he rleterted hy 5 nr.nrnorat! ng a suitably label 1 ed selenium compound
This, in fact, turned out to be correct (Esteban, lesa and Perez-Modrego, 1965),
but it was not realised at that time that the phenomenon of nuclide uptake into
tumours was much more generalized than merely uptake into cartilaginous tumours.
it was not until later when Cavalieri, Scott and Sairenji (1966), and Herrera
et a! (1966), more or le~s simultaneously reported their observations on
75Se-se1enomethionine respectively that this became apparent. The former group
based their clinical study on observations made in sarcoma bearing rats and
75found that a variety of tumours could be detected using Se-selenite. These
tumaurs included cerebral astrocytomas, bronchogenic carcinomas, a case of
myeloma and a case of carcinoma of the colon. These investigators felt that
75Se-selenite was more tumour-specific than any agent previously studied,










































examined showed no significant uptake on scanning. Baptista (1972), has
since studied 58 patients with a variety of hepatic lesions by comparative
scintigraphy using ^^Au or *^Tcm colloid and ^''Se-sel en i te. He has supported
75the suggestion that Se-selenite is more tumour-specific than other agents.
Of 15 patients with benign lesions of the liver (e.g. abscesses, cysts, cirrhosis)
all gave negative scans, whereas the remaining A3 patients with primary or
metastatic liver disease all exhibited positive uptake of "*Se. Esteban et al. ,
75(1972) reported very encouraging but less specific results with Se-selenite
for lesions in the same area. However, there has been little further
75
confirmatory work reported in the literature on this aspect of Se-selenomethionine.
75While scanning the pancreas of a patient with Se-se1enomethionine,
Herrera et al., (1956) observed heavy uptake in a retro-peritonCal mass of
lymphosarcoma. These workers then went on to examine a further 9 patients with a
variety of lymphomas and recorded a gratifying success rate. They also observed
that radiotherapy very quickly caused the increased uptake to return to normal.
75
However, again, it was not appreciated that ' Se-selenomethionine was taken up
by a wider range of tumours than the lymphomas they had examined, and it was
not until further studies were published that this became apparent. D'Angio,
Lokeri and Nesbit (1369) showed that, neuroblastoma in children could be scanned
successfully and hepatomas have also be recorded as exhibiting good **Se-
selenomethionine uptake (Stolzenbert, 1972). Kaplan and Domingo (1972) found the
diagnostic value of liver scanning could be enhanced by using a dual-channel
99 m 75subtraction technique with Tc sulphur-colloid and Se-se1enomethionine.
75
They correlated Se uptake with the vascularity of various types of lesions
as demonstrated by hepatic angiography. Thus, the relatively avascular amoebic ■
12
abscesses and metastases from tumours of the bronchus or pancreas showed little
uptake. It is interesting to note that these results are broadly similar to
those obtained by Lomas, Dibos and Wagner (1972) and Suzuki, Honjo and
£> 7
Hamamoto (1971) who used 'Ga-citrate to demonstrate hepatic lesions. it
may be added in parenthesis here that the importance of isotopic methods in
the differential diagnosis of liver disease is likely to decline somewhat
with the development of grey-scale ultrasonic scanning of this area. Thomas,
Pepper and Owen (1969) showed that uptake occurred not only in malignant thyroid
lesions but also to a lesser extent in benign thyroid lesions.
In a study designed to assess the practical value of scanning
75with Se-selenomethionine in lymphomas and seminomas Ferruci, Berke and
Potsaid (1970) compared the abdominal findings in patients with lymphoma using
75
X-ray lymphangiography and isotope scanning. in fact, the Se-se1enomethionine
method compared quite favourably with X-ray lymphangiography although in one
third of positive 1ymphangiograms, the scans were negative. Conversely,
however, the scan was positive in 251 of cases where the X-ray lymphangiography
was difficult to interpret or reported as normal. Some of these may have been
false positives but the majority indicated disease not initially detectable on
the X-ray. One especially interesting point in this study was the report of
extremely good results in the scanning of seminoma of the testis; this is a
tumour we ourselves have found to be very satisfactorily scanned with ^Ga-
citrate. (Paterson, Peckham and McCready, 1976).
75 ...
Studies of mechanisms of uptake of Se-selenomethionine provide
interesting reading. As mentioned above, the clinical studies on hepatic
75
lesions seemed to indicate some relationship between uptake of Se-seleno-
methionine and tumour vascularity. This aspect has not been adequately examined
in animals and must remain in open question. However, the striking
similarities in the nuclide uptake characteristics of various lesions between
75 67*Se-selenomethionine and Ga-citrate argue strongly in favour of the suggestion
that tumour blood vessel permeability may play an important role in the uptake
of many agents into tumours.
75Since Se-selenomethion 1ne is a labelled essential amino-acid, it
is not unreasonable to postulate that increased rate of protein synthesis within
tumours is a cause of its concentration, and the contribution of protein synthesis
to the uptake of ^Se-selenomethionine has indeed been studied in some detail.
It has been well shown that certain tumours among which are included lymphomas
and seminomas, have a more rapid rate of protein turnover than have normal
tissues (Quastel and Bickis, 1359). Spencer et al (1967) studied the in-
75 ' 75
corporation of Se-selenomethionine into tumours. Se uptake into protein
increased steadily with time in both tumour and liver reaching h0% of the
75total tumour and liver Se at one hour after injection. The concomitant
administration of inhibitors of protein synthesis (Actinomycin D or Puromycin)
75
lowered the amount of Se which was protein-bound, although whether or not
the total tumour uptake was affected is not mentioned.
Although the biochemical and nutritional aspects of selenium
metabolism have been the subject of considerable study, mechanisms of uptake
into tumours other than the possible relationship to protein metabolism outlined
above have not been examined to any great extent. Selenite is a potent oxidiser
of sulphydri! groups (Painter 19^1), and this is a reason for its rapid fixation
in normal tissues, and may account for its accumulation in tumours as well.
Another suggested possibility (Shrift, 1961) is that selenite is metabolised
1'l
by intestinal flora to selenomethionine in which form it might enter the
tumour.
In the last few years other agents such as ^Ga-citrate and labelled
75
bleomycin compounds have taken over from Se labelled compounds as the tumour
imaging agents of choice. There have been no direct comparative studies of
these agents with ^Se-selenomethionine, although the clinical impression
is that the more recent agents have more favourable tumour:background radio-
75
activity ratios. The greatest disadvantage of the Se labelled compounds
75is their long biological half life, which in the case of Se-selenomethionine
is k5 days, and 7"*Se-se1en i te is 65 days.
In conclusion, I would like to draw attention to some of the
striking similarities in the medical conditions producing sufficient uptake
to give scintiscans with 7^Se-selenometh i on i ne and ^7Ga~c i t rate , for
example, lymphomas, ta. bronchus, seminomas, and hepatomas. These similar
conditions inevitably lead one to postulate that there may be similarities
in mechanisms of uptake of some of these compounds. That there are
secondary mechanisms occurring is well illustrated by the experimental
studies described above, but whether these mechanisms are the most important
from the point of view of tumour imaging, remains to be seen.
. 67ga-citrate
^7Gallium is a cyclotron produced radionuclide, which is usually
produced as ^7Ga-citrate by the addition of 3-8?S sodium citrate. It has a
physical half-life of three and a quarter days, and the radiation received
by the patient is less than 1 rad to the whole body and less than 5 rads
to the kidneys.
15
In the fifties, other isotopes of Gallium, particularly Ga
72
and Ga had been investigated as possible new agents for the study of
normal and neoplastic bone metabolism (Dudley, Henry and Lundsly, 1950).
67It was when Ga was being similarly investigated that its uptake was
observed in a group of lymph nodes in a patient v/ith Hodgkin's Disease
(Edwards and Hayes, 1969). When reported, this observation initiated a
great deal of work in both the clinical and scientific spheres mainly
directed to defining the value and specificity of ^Ga as a tumour
localizing agent and explaining the mechanism of uptake.
A 7
Ga localizes in many kinds of tumour. However, the concentration
achieved may be insufficient for scanning purposes particularly in small
lesions. A good example of thi.s occurs in tumours of the stomach and
oesophagus where uptake can be demonstrated in resection specimens but a
clinically useful scan is rarely achieved. Higasi et al . , (1971) found
that, in four cases of carcinoma of the stomach, three cases were negative
and one case was inconclusive on the clinical scans. However, the radio¬
activity in the neoplastic areas of the resected specimens was 2.0-3.2 times
greater than that of the unaffected surrounding tissue ofthe stomach.
Colonic and rectal cancers have also been investigated from this point of
view and despite negative scans, a good concentration has been measured in
the malignant tissue in operative specimens. Therefore, it seems likely
that ^Ga concentrates in many different varieties of malignancy and more
consistently than clinical scanning success rates suggest. Reasons for
failure to detect these lesions may be poor scanning technique; difficulties
in differentiating normal uptake from abnormal uptake (for example in the
region of the liver or where it has been difficult to completely clear the
bowel of faeces) and low tumour:background ratios. It seems unlikely that
16
further improvement in instrumentation will help in these areas and
efforts should be devoted now to improving the relative concentration of
^Ga within malignant lesions. We know that if a tumour:background tissue
uptake ratio of 2:1 is present, a lesion must be at least 2 cm. in diameter
before it will be detected. This is often the kind of ratio that is
achieved in malignancies of the gastro-intestinal tract and may partially
explain the low scanning success rates in such tumours.
However much experience has been gathered in the last few years
6"7
in the use of Ga-citrate. It has become apparent that certain malignancies
are more rewarding than others in terms of acquiring clinically useful scans.
Lymphomas, particularly Hodgkin's Disease and histocytic lymphomas, have a
high success rate (Edwards and Hayes, 1970; Langhammer et al., 1972;
Berelowitz and Blake, 1972). Kay and McCready (1972) at the Royal Marsden
, _ , £-7
Hospital, ana lurner et ai., (iy/2) have examined the place of 'Ga
scanning in the management of patients with Hodgkin's Disease. Both groups
found that there was a 10% detection rate in areas of active disease. Kay
and McCready, in addition pointed out that the technique was useful in
detection of mediastinal disease. They cited six patients with normal
chest x-ray where ^Ga showed increased uptake in the mediastinum, who
subsequently went on to develop clinically overt llodgkin's Disease. They
also pointed out the value of ^Ga-citrate in the differentiation of fibrosis
from recurrent tumour.
Bronchogenic carcinomas (Higasi et al, 1971; I to et al., 1971;
Muhe, 1971), hepatomas (Higasi et al., 1971; Suzuki, Honjo and Hamamoto,
1971; Lomas, DiBos and Wagner, 1972; Winchell et al., 1970) osteosarcomas
17
(Okuyama et al., 1972; Berelowitz and Blake, 1972), carcinomas of the maxilla
(Higasi et al., 1971; Berelowitz and Blake), all show consistently high
scanning success rates. I to et al., (1971) stated that in carcinoma of the
G7
bronchus, Ga scanning was very useful for the detection of infraclavicular
nodes difficult to palpate clinically, and mediastinal metastases difficult
to demonstrate radiologically, while Muhe (1971) suggested that this was
the simplest method for detecting recurrences and was more accurate in
differentiating a malignant from a benign tumour than bronchoscopy, media¬
stinoscopy or sputum examination.
Investigating over 60 patients who had focal defects on colloid
liver scans Lomas et al. (1972) found that increased specificity of diagnosis
was achieved when ^Ga scanning was also performed. The physiological uptake
/ -i /
of Ga over the liver makes interpretation in this area difficult on Ga
67 99m
scanning alone, while the two isotopes together ( Ga and Tc) helped to
differentiate cancer and abscesses from more benign causes of an abnormal
liver scan. In particular, cirrhotic livers giving "patchy" colloid scans
where doubt existed as to the possibility of development of a hepatoma, could
be investigated with ^Ga, a localized area of high uptake being highly
suggestive of hepatoma. Hepatomas, indeed, invariably show increased ^Ga
uptake, in contrast to intrahepatic secondary deposits, which are often not
demonstrable. Only four of nine patients with liver metastases from an
adenocarcinoma showed uptake in Lomas's series. An explanation for this
was put forward by Suzuki et al., (1971) who reported the same phenomenon.
In an elegant study, this group performed selective hepatic arteriography
6 7
on 25 patients with liver cancer. Radioactive gold-colloid and Ga scans
were done on the same patients. They found that the highly vascular
f) 1
hepatomas invariably concentrated Ga, whereas the avascular secondary
18
metastases showed little concentration. Those secondaries with moderately
well developed tumour circulations showed moderate Ga uptake.
99 m
Tc pertechnetate is probably the most suitable agent for routine
scanning of suspected intracranial lesions, but there are occasions when
^Ga-citrate brain scanning can give additional information as outlined by
Jones et al., (1972). One third of the cases in this series were more clearly
67 67shown using Ga-citrate, but most usefully, Gallium did not appear to be
Q Q
taken up by the craniotomy bone-flap, as is Tc pertechnetate. Gallium
scans, therefore, can aid in the differentiation of recurrence of residual
tumour from uptake at the operative site. Interestingly, the Bethesda
group also described two cases, one a brain metastasis from a bronchial
adenocarcinoma and the other a glioblastoma multiforme, both of which had
received radiotherapy or chemotherapy very shortly before the scans were
67 99 mdone. The Ga scans showed poor uptake whereas the Tc scans clearly
imaged the tumour. The implication of this is, of course, that shortly
after treatment the vascular space within the tumour was unchanged but that
the treatment interfered with the mechanism of uptake of ^Ga. It has frequently
^ 7
been demonstrated that Ga uptake decreases to normal levels after successful
C 7
treatment of an involved area and it may be that Ga studies will provide a
sensitive and early indicator of effective treatment.
Less consistently successful scans are obtained in malignant
melanoma (Berelowitz et al., 1972; Lavender et al., 1971; Langhammer et al.,
1972; Milder, 1973) hypernephroma (Berelowitz and Blake, 19/2; Antoniades
et al., 1973), carcinomas of the breast (Lavender et al., 1971; Fogh and
Edeling, 1972), colon and rectum (Nash et al., 1972; Langhammer et al., 1972),
and thyroid (Edwards and Hayes, 1970; Langhammer et al., 1972).
19
Intra-ocular melanoma deposits have given particularly
disappointing detection rates. • Heuer, Ehlers and Hansen (1972) examined
nine patients with malignant melanoma of the choroid. ^Ga accumulation
did not occur in any of the cases. These were, however, very small tumours
most having a range of diameters from 0.5-1.5 cm. He concluded rightly
that for ophthalmologists "the method does riot in its present form offer
any clinical information."
6 7
Very variable results have been reported in Ga scanning of carcinoma
of the breast. I to et al. (1971) have reported a good scanning success rate,
while others have had singularly poor results. Lavender et al . (1971)
examined 25 patients with carcinoma of the breast. Of 12 patients with operable
primary tumours, none gave positive scans. Nine of 13 patients with metastatic
or advanced lesions gave positive scans. Here again, tumour size may have
been important in the detection of these iesions. This group reported
uptake in breast abscess.
Colonic and rectal tumours have been observed by various investi-
6 7
gators to concentrate Ga sufficiently to produce a positive scan in approximately
h0% of cases. Normal faecal excretion of the isotope makes bowel washouts
necessary if good scans are to be obtained. As has been previously mentioned,
although this is rather a low clinical success rate, it must be compared to
increased tumour:background ratios which occur far more frequently than
the detection rate suggests. Nash et al. (1972) examined the uptake of
^Ga in 20 resection specimens of colonic and rectal disease, predominantly
malignancies. In 13 out of 15 malignancies the tumour:normal tissue ratio
was greater than 2:1. In five of the tumours, the ratio was greater than
5:1. An attempt was made to correlate the pathology of the tumours with the
uptake. The tumours were graded as poorly, moderately or well differentiated.
The degree of differentiation of a tumour only implies that a growth rate is
fast or slow, and mitotic indices or tritiated thymidine labelling indices
were not done in this study. However, generally it was found that the poorly
f) 1
differentiated tumours took up Gallium more avidly than either the moderately
or well differentiated tumours, and the moderately differentiated ones took
up slightly more ^Ga than the well differentiated ones. The ^Ga activity
in cross-sections of the growths was measured and the greatest activity was
found in the actively growing tumour edge while the necrotic centre showed
low uptake. This parallels other observations that ^Ga localizes in viable
tumour cells and not in necrotic tumour (Hayes, Nelson and Swartzendruber,
1970). Suprisingly, there have been no more detailed studies of ^Ga uptake
and the degree of tumour differentiation and growth rate in human cancer
although several attempts to correlate ^Ga uptake with histological tumour
cell types have been made without success (Van der Schoot, Groen and Jong,
1972; Siersbaek-Nei1 son , Hansen and Fris, 1972).
There is no doubt that ^Ga scanning in its present form offers
little clinical help in gynaecological malignancies and carcinomas of the
oesophagus, stomach and pancreas (Higasi et al., 1971). As has been said
before, concentration occurs but it is often insufficient for scanning
purposes.
Hopes that ^Ga~citrate was a truly specific malignant tumour scanning
agent were unfounded when reports began to be published showing uptake in
a variety of lesions. It has been demonstrated that ^Ga is taken up by
abscesses in a variety of sites. These included breast (Lavender et al.,
1971), ovary (Symmonds and Tauxe, 1972), gallbladder (Lomas and Wagner, 1972)
and psoas muscle (Fratting and Sharp, 1973). Lomas and Wagner (1972) suggested
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that since the uptake of ^Ga had been observed in four consecutive cases of
gallbladder empyema, ^Ga scanning might be of value in the pre-operative
diagnosis of inflammatory gallbladder disease since a negative oral chole-
cystogram is a non-specific finding. Geloud, Arseneau and Johnston (1973)
examined uptake of ^Ga in experimental sterile and infectious abscesses
and found on autoradiography of the abscess aspirates, that radioactivity
was confined largely to the "inflammatory" cells.
Other inflammatory lesions which have been recorded as giving
positive scans are pneumonia both bacterial and viral(Kinoshita et al.,
1973)', tuberculosis (Dige-Petersen, Heckscher and Hertz, 1972) and subacute
thyroiditis (Grove, 1973). The cases of tuberculosis which concentrate
^Ga are generally those of "active" disease, chronic cases on the whole
6 7
showing no uptake. Active sarcoidosis invariably concentrates Ga, to the
f -7
extent that U/Ga scanning could be performed as a monitor of disease progress.
It is my own and others experience that ^Ga does not concentrate
v/ithin post-irradiation fibrosis. This is very useful in the differential
diagnosis of tumour recurrence from post-treatment fibrosis. However, in
other fibrotic diseases, such as silicosis, there is often a diffuse, light
uptake (Winsor et al., 1973).
C-j
Investigation of the mechanism of uptake of Ga by tumours and
other tissues together with clinical studies will form the major part of this
thesis.
Id). RECENTLY DEVELOPED TUMOUR IMAGING AGENTS
1. LABELLED BLEOMYCIN COMPOUNDS
Radionuclides chelated by bleomycin have been used widely in the
last few years. Bleomycin is a polypeptide antibiotic with cytotoxic effects
(Umezawa et al., 1966; Tukeuchi and Yamamoto, 1968). Its distribution has been
studied in animal tissues and it has been found to concentrate in skin,
peritoneum, and to a lesser extent, lung tissue (Umezawa et al., 1968).
Limited work has been done on its distribution in tumour-bearing mice, and
it has been found to concentrate well in chemically induced squamous carcinomas
of the skin and to a much lesser extent in skin sarcomas and brain gliomas
(Umezawa et al., 1968; Hayakawa et al., 197*0. Clinically, it has been
found to have some therapeutic effect in certain cancers, particularly squamous
carcinomas of the skin (Blum, Carter and Agre, 1973), and testicular tumours.
The first radionuclide chelated to bleomycin to be used in humans was
^Co. Nouel and his colleagues (1972) examined ten patients suffering from
a variety of malignant diseases and found that good scans were obtained in nearl
57all the patients. Co-bleomycin has been shown to concentrate more favourably
6 2
in experimental tumour-bearing animals than either Zn-bleomycin (Taylor
Q Q m
and Cottrall, 1973), Tc -bleomycin (Lin, Goodwin and Kruse, 197*0,
^Cu-bleomycin (Hall and O'Mara, 197*0 and ^'In-bleomycin. The last of
these has probably been the most extensively investigated. ^In has a
suitable half-life (67-5 hours) for use in patients, and emits two easily
detectable spectrons of gamma radiation in cascade in abundance (171 keV
89% and 2*t7 keV SU) .
Several clinical series have now been reported using this agent
and although some of the reports are enthusiastic, it appears that this agent
does not offer any real advance over ^Ga-citrate jn terms of improved
tumour:background ratio. However it must be said that the faecal and small
bowel uptake of ^Ga can make interpretation of abdominal scans difficult
and '^In-bleomycin scans of the abdomen are much more easily read because of
the rapid excretion of ^'ln by the kidneys.
Li lien and his colleagues (197*0 felt that the agent offered a
significant advance in tumour diagnosis by demonstrating a wider range of
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tumours than ^Ga-citrate. They describe good uptakes in lymphomas and
carcinomas of the bronchus and colon, but striking results were obtained
with ovarian carcinomas (88% successful imaging) and melanomas (100% successful
£ "7
imaging). These tumours tend to be poorly demonstrated by Ga-citrate. It
is possible that Bleomycin's peculiar property of concentrating in skin and
peritoneum has influenced the uptake of the agent in these cancers. The
agent, again, is not specific for malignant lesions, positive scans having
been recorded in a variety of inflammatory diseases. In the studies published,
there are unfortunately no control scans with which to compare the agent
being tested. Useful information in the clinical field can only be acquired
by comparing any new agent with the best currently available and consequently
a clinical comparative study of '^In-bleomycin and ^Ga-citrate will be
described (Paterson, Taylor and McCready 1975) in a following section.
The metabolism of ^'In-bleomycin has been studied by Goodwin et
al. (197*0 among others. The kidneys excreted 70-80 per cent of the agent
in the first 2b hours in humans. The remainder had a long biological
half-life, with increasing marrow acitivity, which suggested that ^ln-
bleomycin, initially tissue fixed, was being broken down and ^'ln-
transferrin was being transported to the bone marrow.
Nevertheless, ^ In-bleomycin represents a deliberate approach
to the problem of tumour imaging by attempting to increase tumour uptake using
a cytotoxic agent and to decrease tumour:background activity by modifying
the mode of excretion of ^''ln.
2. RAD10LANTHANIDES AND OTHERS
These rare earth elements of high atomic number have been found
to concentrate within tumours by Hisada and Ando (1973). They have recently
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investigated 15 patients using Ytterbium-citrate with good scanning results
2k
in primary liver and lung cancers, lymphomas and bone metastases (Hisada
et al., 197*0 • However, these are the kind of tumours which may be successfully
imaged using ^Ga-citrate. The tissue and subcellular distribtuion of the
radiolanthanides has been compared to ^Ga-citrate by Hayes et al., (197*0.
They found that these agents had comparable tumour localizing ability and a
similar subcellular distribution to ^Ga-citrate, and furthermore, tended
to concentrate at site of inflammation. This would suggest that in tumour
67
imaging, the radiolanthanides do not offer much more than Ga-citrate.
Recent approaches to the problem of tumour imaging have included
1 31the tagging of tetracycline with I (Chauncey, Halpern and Alazraki, 197**)
and the use of labelled metabolites tailored to the particular tumour being
investigated (Forman et al., 197**). A most interesting approach to the problem
1 31
has been the labelling of antibody to carcino-embryonic antigen with I
(Hoffer et al . , 197**)- This may be useful in the diagnosis of gastro¬
intestinal tract tumours although high levels of circulating C.E.A. may well
be a problem.
However, in ordinary clinical practice, most departments use
^Ga-citrate for routine tumour imaging and this thesis will deal predominately
with the clinical significance and mechanisms of uptake of 'Ga-citrate in
malignant tumours.
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2. CLINICAL COMPARATIVE STUDIES OF TUMOUR IMAGING
RADIOPHARMACEUTICALS
1. A Clinical Comparison of the Tumour Imaging Radiopharmaceuticals
^Ga-citrate and ^Indium-labelled bleomycin.
The main part of this section was published in the
British Journal of Radiology, A8, 832-842 (1975)
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JL INTRODUCTION
Clinical studies of tumour imaging agents have concentrated
mainly on the question of the tumour specifity of the agent under
investigation. Papers have tended to focus on whether or not a
known malignant lesion, easily demonstrable by other means, could
be demonstrated by scanning. In other words, it would appear that
to many investigators, the most attractive features of these agents
is their potential value in differential diagnosis. However, it
has been shown time and time again that these agents have the
property of uptake in a certain proportion of inflammatory and
granulomatous disorders. We feel, therefore, that their value
in differential diagnosis must be limited to situations where
inflammation can be reasonably excluded, such as the differentiation
of post-irradIation fibrosis from recurrence of tumour in the lung.
A gallium scan under these circumstances can be most rewarding
cl inically.
Thus, clinical interest is likely to turn to other advantageous
features of this diagnostic method, and- one of the most obvious is
the case in which the whole body may be scanned for the staging of
a proven malignant lesion. To this end, improvement in tumour:background
ratios must be sought.
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Bleomycin is a polypeptide antibiotic with cytotoxic properties
and is effective in the treatment of certain squamous carcinomas in
animals and man (Umezawa et al., 1966; Takeuchi and Yamamoto, 1968;
Blum, Carter and Agre 1973) and testicular tumours (Samuels et al.,
1975). Studies of its distribution in mice have shown high
concentrations of the drug in skin, peritoneum and, to a lesser
extent, lungs (Umezawa, Ishizaka and Hori, 1968), but there is only
limited evidence for its actual concentration within tumours. Uptake
measurement of "H-bleomycin into squamous carcinomas of skin and skin
sarcomas in mice have shown that concentration occurs in the carcinoma
to a much greater extent than in the sarcoma (Umezawa, 1973). Using
^C-bl eomyc i n, Hayakawa et al., (197*0 demonstrated tumour: normal tissue
ratios of 3:1 in chemically induced gliomas in mice. No other tumours
in animals or mar. have been examined.
The drug has chelating properties, thereby facilitating
57
radiopharmaceutical production. Using Co-labelled Bleomycin, Nouel,
Renault and Robert (1972) studied ten patients with a variety of
malignancies and found that this agent gave good scans in all the
patients studied. However, the long half-life of *^Co (270 days) is
a disadvantage and consequently other more suitable radionuclides have
Q O pj-\
been investigated. These have included Tc ' bleomycin (Lin, Goodwin
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and Kruse, 197*0, Zn-bleomycin (Tayior and Cottrall, 1973),
k^Cu-bleomycin (Hall, O'Mara and Cruz, 197*+) and ^ ^ I n-b 1 eomyc i n.
Because of its more favourable physical characteristics,
^ Mn-b1eomycin has been widely used as a tumour imaging agent and
many reports have been published. The only way to properly assess this
28
new agent was to compare it in the same patient with the currently
most widely used tumour imaging agent, ^Ga-citrate. This study,
therefore, reports the results of a comparative trial of
111, L1 . j 67,In-bleornyci n and Ga-citrate.
METHODS
This comparative study was divided into two sections. One
part dealt with the relative scanning qualities of ^In-b1eomycin
67and Ga-citrate and the other was a quantitative study of the
relative uptake of the two radionuclides in biopsy samplings
removed at operation.
in Llie fiibt par i of the study, 25 patients received both agents.
Of these, one patient was examined with the two agents on three
separate occasions and one patient was examined twice. Therefore,
in all 28 examinations were performed. Whole-body scanning, using
both agents, was performed to fully establish the total extent of
disease. In those in whom scanning was of academic interest only,
informed consent was obtained.
Eighteen of the 26 patients were examined during the initial
period of investigations prior to treatment. In ten examinations,
treatment with either chemotherapy or radiotherapy had to be given
between scans. These cases will be dealt with separately since the
possible effect of treatment on uptake requires individual
assessment.
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The diseases of the patients studied were: Hodgkin's disease
(13 examinations), carcinoma of the bronchus (4 examinations),
seminoma testis (3 examinations), non-Hodgkin1s lymphomas
(2 examinations) and osteosarcomas (2 examinations). One case
each of malignant melanoma, myeloma, hydrocoele and carcinoma of
the ovary were also examined.
The scans were performed as far apart from each other as was
reasonably possible in order to diminish any possible effect one
agent might have on the mechanism of uptake of the other.
Nevertheless, in 13 examinations, the time interval between scans
was only one week. Here, it is possible that the y-emission from
the first agent could contribute to the scan obtained after the
■i t *
second agent had been given. In these 13 examinations, ln-bleomycin
was the first agent given on seven occasions followed by
^Ga-ci trate. When ^Ga-ci trate was given before the ^ ^ In-bleomycin ,
it was relatively easy to exclude any effect the previously
administered ^Ga-ci trate might have on the ^ ^ I n-b 1 eomyci n scan by
using the 147 keV peak of ^ In with a narrow window setting of
230-270 keV. However, it is not possible to exclude previously
administered ^^ln by using a selective wi ndow./sett i ng. Under these
circumstances, a scan was performed prior to administration of the
^Ga-ci trate to make sure that an increase in tumour :bac.kground ratio
after the 48 hours had not occurred, since this might have caused
/* ~1
enhancement of the Ga image. It must be added that this would be a
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most unusual effect, and, furthermore, since three half-lives of
111
In decay had already occurred it would be most unlikely that the
energy emitted from the ^In would affect the scan obtained with
the ^Ga. Under these circumstances, no increase in tumour:
background ratios was observed to occur over the week following
111
the administration of In-bleomycin and therefore these
scans are directly comparable. Eleven examinations were performed
with two weeks interval between scans (on six occasions
^Ga-ci trate was given first, and on the remaining five,
111
in-bleomycin was given first), and the remaining five examinations
were conducted at three or more weeks interval between scans.
Carrier-free ^In-b1eomycin (bleomycin concentration 1 mg ml
was obtained from the M.R.C. Cyclotron Unit, Hammersmith Hospital and
latterly, from the Radiochemical Centre, Amersham, when the
bleomycin concentration in the ^ I n-b1eomycin was 0.66 mg ml \ In
both types there was approximately 1mCi of ^In per ml. of isotonic
saline, and therefore, the ^In-bleomycin from the M.R.C. Cyclotron
Unit contained more bleomycin per unit of radioactivity than the
^^In-bleomycin from the Radiochemical Centre.
It is possible that slight differences in rates of excretion of
^^In-bleomycin from the different suppliers might be observed, althou
it was not felt to be of much significance in this study. It was
administered intravenously in doses ranging from 1-2.3 mCi depending




Carrier-free Ga-citrate was obtained commercially from
Phi 1ips-Duphar and was administered intravenously in doses
ranging from 1.5 to 3.2 mCi, most patients receiving 2.5 mCi.
Scans were performed on a Selo Superscanner D.S.7. forty-eight
hours after injection of either radiopharmaceutical.
The second part of the study was concerned with the direct
measurement of the uptake of the two agents in biopsy specimens
removed at operation. Thse specimens were mainly lymph nodes
and spleen (some specimens involved with lymphoma, others normal)
from patients undergoing staging laparotomies for Hodgkin's disease
or non-Hodgkin 1s lymphomas. Approximately 500 jrjCi of ^in-bleomycin
£) 7
and 500,/itCi of Ga-citrate were given together intravenously 2b hrs.
before operation. Blood samples were taken at 1, 3, and 2b hours after
the injection. At 2'i hours, the biopsy was performed and specimens
were taken immediately for measurement of the relative uptake of
111. i . . . 67r ,!n-bleomycin and Ga-citrate.
The samples of whole blood plasma and tissue were assayed for
^Ga and ^ In in order to ascertain the range of concentrations
occurring within the tissue.
32
RESULTS
The results of 28 separate examinations in 25 patients are
given in Tables 2.1 and 2.2. Table 2.1 lists the results of those
examinations performed during the initial diagnostic work-up.
Table 2.2 lists the results of examinations performed where treatment
has been given at some time before or between the scans.
The term "clearest image" is se1f-exp1anatory, the clearest
images having the highest 1esion:background radioactivity ratios.
Obviously, the clearer the image, the lower the number of false
negative interpretations. It is of course necessary to ascertain that
the images obtained did actually delineate tumour, and therefore
correlation with clinical findings was assessed. Because of the
variable number of disease sites in an assortment of different tumours,
there were some difficulties in grading clinical correlation.
However, it was finally decided to use four broad assessment
categories. These were:
GOOD - Tumour imaging coincided with eventual clinical and pathological
staging;
FAIR - if one site of disease was missed or was equivocal;
POOR - if no abnormal uptake occurred in the presence of known disease.
In separate examinations, the ^Ga-ci trate scan was superior
to the ^^In-bleomycin scan. There were no examinations in which the
^




































































































































































































































































































































































































































































































































































































in lA examinations, the scans were similiar. Clinical correlations
are given in Table 2.3.
The photographs of the scans illustrate typical grading
assessments of the clarity of tumour image. They show quite clearly
67
the superiority of Ga-citrate as a tumour imaging agent in these
clinical situations (Figures 2.1 - 2.6.).
The concentrations of ^Ga and ^ln found in 17 samples of
spleen removed 2k hours after simultaneous administration of
^Ga-ci trate and ^ ^ In-bleomycin are listed in Table 2.If. The data
are listed as the percentage of the administered dose per kilogram
wet tissue ± one Standard Deviation, between four and ten individual
samples of each spleen were assayed. Seven of the 17 spleens
examined showed macroscopic or histological evidence of infiltration
by tumour.
Similar data for nine samples of liver and six samples of
lymph nodes are also present in Table 2.5.
Concentrations of ^Ga and ^ In were compared in whole blood and
plasma samples during the first 2k hours after administration in
18 patients. IN 13 patients the rate of clearance of ^ In from the
blood was slower than that of ^Ga, a typical set of clearance curves
is illustrated in Fig. 27A. Four patients showed a more rapid
clearance of ^ In than that of ^Ga. In two patients the clearance
of ^In was exceptionally slow; the loss from the blood between one
hour and 70 or 120 hours approximating in each case to a
exponential with half-times of 85 hours and 70 hours. One of these
cases is illustrated in Fig. 27B. The tissue to blood concentration











Correlation of ^Ga-citrate and ^^ In-bleomycin scans to ultimate




































































































































































































































































































































































































Tissue to blood ratios in spleen, liver and lymph nodes
2k hours after ^Ga citrate and ^In-bleomycin.
67Ga '"in
Mean Range Mean Range
Spleen 3-0 1 ,.5 to 13-.8 1 .3 0.2 to 5..k
Liver 5.k 1 . ■ 9 to 13..8 2 .2 0.5 to k,.8




he disappearance of 67Ga and luIn from the blood follow-
g simultaneous administration of 67Ga-citrate and 111In-
.eomycin. Patient C.T. illustrates the clearance pattern
^served in the majority of the patients studied. Patient
.M. illustrates the abnormally slow clearance by mIn
observed in two patients.
4i»
spleen, liver and lymph nodes are listed in Table 2.5.
DISCUSSION
It is essential that the clinical assessment of tumour-imaging
agents in the future should be by controlled trial. The initial
enthusiasm for a new diagnostic agent is understandable, but little
knowledge can be gained from the publication of scanning results
using a single agent other than that the agent is suitable for
assessment. It is known that certain tumour-imaging agents, for
example ^Se-sel enomethi on ine , ^"^Hg-ch 1 ormerodr i n , ^Ga-ci trate
and ^^ln-bleomycin, can all demonstrate a proportion of malignant
lesions in a ranqe of tumours: what we do need to know is whether a
particular agent demonstrates particular groups of tumours or
whether one tumour-imaging agent gives higher tumour-background
radioactivity ratios than another.
In this study, it has been shown that ^Ga-ci trate is a more
useful tumour-imaging agent than ^^In-bleomycin both in clinical
correlation and In the quality of image obtained for lesions
situated above the diaphragm. It is difficult to evaluate the
place of ^^ In-bleomycin in the detection of abdominal tumours
because insufficient numbers of infradiaphragmatic lesions have
been scanned from Hodgkin's disease. ^^ !n-bleomycin1s favourable
property of renal excretion together with the known affinity of
bleomycin for serous membranes may make it a useful agent for the
^5
detection of gut and pelvic tumours. Uptake into faeces and small
£ "J
intestine is a well-known drawback to the use of Ga-citrate in
the demonstration of such tumours.
There have been a number of trials investigating ^^In-bleomycin
as a tumour imaging agent. Li1ien et al (197^) have reported very
high scanning success rates in neoplasms normally difficult to detect
by scanning techniques. They had successful scans in all of 1A
patients with malignant melanoma, but ithein most remarkable
figures were 88 per cent positive scans in 15 patients with
ovarian carcinomas. Using ^Ga-ci t rate, Symmonds and Tauxe (1972)
had disappointing experiences in gynaecological tumours,
particularly squamous cell carcinomas of the cervix. Clearly the
scanning of gynaecological malignancies with ^^In-bleomvcin needs
full appraisal, although in our one patient with a large ovarian
carcinoma, neither the ^In-b1eomycin nor the ^Ga-citrate scans
showed the tumour. The same group (Jones et al., 1973) earlier
reported their work in lymphomas, finding a 79% overall accuracy
in the prediction of disease sites, which is si mi liar to
^Ga-citrate studies in these conditions (Kay and McCready, 1972;
Turner et al., 1972). Goodwin et al (197^0 reported a 69% scanning
success rate in a variety of tumours and Verma et al. (1973)
reported an overall success rate of 79%.
However, diagnostic success rates using tumour imaging
agents depend not only on the type of tumour but also on the area
*t6
and extent of disease. When only one agent is used, the results
can be misleading in the assessment of that agent, and a study
comparing two or even more agents, is more helpful in the
assessment of that agent. This suggestion is supported by a
recently published trial by Grove et al., (197*0, who compared
111, .67„ . . 57^ ,,
scans using In-b1eomyc1n, Ga-citrate and Co-bleomyc1n.
57The Co-bleomycin seemed to be better than those obtained with
67
Ga-citrate and clearly one of the next steps is to investigate
57
Co-bleomycin more thoroughly and decide whether the possible
57
advantages of Co-bl eomyc i ri outweigh the disadvantage of its
long physical half-life.
The mechanism of uptake of V In-b1eomycin into tumours, like
other tumour-imaging agents, is not clear. It has been suggested
that it is the bleomycin which increases the concentration of
^^In-bleomycin by its own concentration within tumours. There
is, in fact, some evidence that concentration of bleomycin actually
occurs in certain mouse tumours. It is not clear, however,
whether ^In actually enters the tumour as ^In-bleomycin. It is
likely that the improvement in tumour:backg round ratio of
^^In-bleomycin over ^^In-transferrin is due to the rapid renal
excretion of ^ In-bleomycin thereby rapidly lowering background
activity. If the chelate is not completely stable, as it would
appear not to be (Goodwin et al . , 197*0, ^ ^ In-transferr in will be
formed to some extent and background activity will be heightened.
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At a cellular level, the reason why ^^ In-bleomycin or
111, r .In-transferrin enters tumours remains unknown.
In the second part of this study the uptakes of
^Ga-citrate and ^ ^ In-bleomycin in involved and normal lymph
nodes, spleen and liver, removed at operation were measured. In
addition, the blood clearance of the two agents was measured over
the twenty-four hours prior to operation. Broadly, these results,
although restricted to lymphomas, have tended to support the
clinical observations, although one or two exceptions have been
noted.
Comparison of the data presented in Table 2.4 shows that in
the spleen, liver and lymph nodes there are wide variations in
uptake both between the two nuclides and between different
tissues. In the spleen, nine of the 17 samples contained more
^Ga than ^ln and eight contained more ^ In than ^Ga; the
ratios of the highest and lowest concentrations observed were 6:1
for each nuclide. Only two out of seven samples of lymph nodes
contained more ^ln than ^Ga but this tissue showed the greatest
range in the concentrations of the two nuclides in individual
samples, the highest to lowest concentration ratios being 36:1
for ^Ga and 22:1 for ^ln. The concentrations of ^Ga observed
in spleen and liver were similiar to those previously reported by
Saunders, Taylor and Trott (1973).
Seven of the spleen samples were infiltrated with tumour and
five of these contained less ^Ga than ^ln; in contrast, four of
the five tumour-infi1trated lymph nodes showed ^Ga concentrations
greater than those of ^ In. None of these variations could be
simply correlated with the type or stage of the disease.
The rate of clearance of the two nuclides from the blood
showed considerable variation and the tissue to blood concentration
ratios varied widely as is seen in Table 2.5- The rates of
clearance of ^Ga from the whole blood and from the plasma were
similiar to those reported in earlier studies (Saunders et al., 1973)-
The clearance of ^In from both the whole blood and plasma showed
greater variation than that of ^Ga. In most cases the clearance
of ^ In from the blood was slower than that of ^Ga and two cases
showed an unusually slow clearance of ^in. The majority of the
cases did not show the rapid initial clearance of ^In from the
blood with half-times of about 15 minutes which have been reported
by other workers (Williams, Merrick and Lavender, 197^: Goodwin et
al., 1973). The reasons for this slower clearance are uncertain
but it may possibly reflect the fact that most of the cases were
patients in whom the tumour mass was small. In another study the
clearance of ^In-bleomycin from the blood was studied in an
18-year-old man suffering from Hodgkin's disease and with a large
mass in the mediastinum. At the commencement of treatment, with
radio- and chemotherapy, 97% of the ^^ln disappeared from the
blood in 2k hours, but two, four, and nine weeks later when the
mediastinal mass had almost entirely disappeared, the rate of blood
clearance had slowed and only 90% of the dose disappeared during the
^9
first 2b hours after an injection of 111In-bleomycin. Thus it
seems possible that the presence of large tumour masses may
result in a more rapid clearance of ^ln from the blood after
injection of the bleomycin complex.
The results of these studies of the tissue uptake of ^Ga
and ^l|n, after administration as the citrate and bleomycin
complexes respectively reinforce the conclusion drawn from the
scanning studies that ^^1n-b1eomycin offers no advantages over
67Ga-ci trate for the investigation of lymphomas (including
Hodgkin's disease) and other tumours situated above the diaphragm.
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2b: A CLINICAL COMPARATIVE STUDY OF THE TUMOUR IMAGING AGENTS
67GALLIUM-CITRATE AND 57CO-BLEOMYCIN
A summary of this section has been submitted as a letter to the
British Journal of Radiology (to be published)
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INTRODUCTION
Reports from France (Nouel et al 1973) and from the United
States (Grove et al 1975) have suggested that bleomycin labelled
57 ®
with Co is a useful tumour imaging agent. The rationale for
the use of labelled bleomycin has been examined in a previous
57
section. Co forms a stable chelate with the polypeptide
bleomycin and, unlike ^ln, localization of **^Co in the bone
marrow is not a problem. The main disadvantage of using a
57radionuclide such as Co is its long physical half-life
(270 days) which gives rise to problems of waste disposal.
METHODS
The patients with their informed consent, received 1 mCi of
57
Co labelled bleomycin intravenously, blood samples being taken
at 1, 3, and 24 hours and urine being collected for 2b hours after
the injection. Scanning was carried out at 6 hours and 2b hours
after the injection. Approximately one week later, the same
patients received 2.5 mCi of ^Ga-citrate and were scanned 48
hours later.
57
For the ^parotomy studies, 100 mCi of Co-bleomycin and
250 mCi ^Ga-citrate were injected intravenously 2b hours prior to
operation. Blood samples were taken at 1, 3, and 24 hours after
the injection. Biopsy samples were cut into five or more pieces
52
weighed and assayed for ^Co and ^Ga. Standards of the injected
agents were also assayed.
The following settings were used:
S7
Co Peak Channel 1.
0.5 MeV upper 6.0 - lower 5.0 Channel 2.
57
Using these settings there was no Co spillage into the
67 67
Ga channel, but Ga gave approximately 1.2 times the amount in
the *^Co channel as in the ^Ga channel.
RESULTS:
Nine patients with a variety of tumours were scanned with
r-i £ -7
Co-bleomycin and also received a control scan with Ga-citrate.
Two patients did not receive ^Ga-citrate control scans. Two
patients had large inoperable carcinomas of the pancreas which
57 67
failed to image either with 'Co-bleomycin or Ga-citrate. In
2 patients, one with a carcinoma of the bronchus and one with
£ 7
Hodgkin's disease the Ga-citrate scan was unequivocably superior
57
to the Co-bleomycin. in one patient with a malignant pleural
57
effusion, the Co-bleomycin scan was superior in that there was
a diffusely increased area of uptake in the region of the pleural
67effusion whereas the Ga-citrate scan was negative.
The results of the biopsy specimens taken at laparotomy for
the staging of Hodgkin's disease after receiving small doses of
£-7 £ -7
Co-bleomycin and Ga-citrate are given in Table 2.8. In all,
seven patients were studied. As can be seen from the Table,
the tissue:piasma ratios of the biopsy samples were usually
higher for *^Co thai for ^Ga, although the absolute amounts of
radionuclide detected were considerably greater for ^Ga than for
^Co. The significance of this will be discissed in the next
section.
DISCUSSION:



















































































57The low amounts of Co detectable led to extremely low information
densities which meant unacceptably long scanning times in a busy
department dealing with ill patients. It is interesting that the
biopsy specimens of spleen and lymph nodes which were involved with
57
Hodgkin's diease showed higher tissue:piasma ratios for Co than
67 c7for Ga. However, the absolute amounts of ^ Co present were often
so low that using currently available instrumentation, scanning would
have presented a major problem due to low information densities.
57Clinical studies using Co-bleomycin have been reported by
Mamo et al (1973), Suzuki et al (197*0, and Grove et al (197*0 • In
the study by Mamo et al (1973), *^Co-bleomycin was found to be
Q Q pp|
superior to Tc for the detection of intracranial metastases
99 m
although for meningiomas and qliomas. Tc appeared to be
superior. Grove et al (197*+) compared ^Co-bl eomyc in scans with
^Ga-ci trate in 15 patients, finding that a slight superiority in
imaging was obtained with "^Co-b leomyci n.
In view of our results which appeared to be at variance with
those of other centres, chromatography was performed on blood and
urine specimens and standard distributions were obtained showing
that no dissociation of the injected material had occured.
Although the scanning results in this series were disappointing,
57
the biopsy results do suggest that Co can localize in tumours in
higher relative concentrations than ^Ga, although the absolute
amounts of "*^Co in the body is so small that scanning is extremely
difficult and time consuming. It may be that certain tumour types
56
concentrate Co preferentially as suggested by Mamo et al
(1973)- However, in our hands, the possible advantages of
57
Co-bleomycin did not outweigh the disadvantages associated with
the use of this agent on a large scale.
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3• THE CLINICAL SIGNIFICANCE OF 67Gallium Uptake
1. Hodgkin's Disease
A modified version of this section has been submitted
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Gallium-citrate ( Ga-cit rate) whole-body scanning
has been used in the management of Hodgkin's disease for
/ 7
several years. Currently Ga-citrate scanning is used
for initial staging, and in cases of suspected relapse.
Most of tiie reports on the use of ^Ga-citrate scanning in
Hodgkin's disease have concentrated on its place in
clinical management. This paper attempts to relate
^Ga uptake to the disease process. It was stimulated by
the clinical impression that high uptakes in disease areas were
seen in ill patients, patients in relapse or patients with
widespread disease. On the other hand, there are occasional
cases where large tumours in areas such as the mediastinum
show little or no concentration of Ga-citrate. A
retrospective study of ^Ga-citrate scans has been performed
in patients scanned over the last five years at the
Royal Marsden Hospital, Sutton, in an attempt to correlate
^ 1various clinical parameters with the level of Ga
radioactivity.
METHODS
The patients in this study
untreated patients, or patients
treatment.
were either previously
who had relapsed following
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Between 2-3 m C i of ^Ga-citrate (commercially
obtained from Phi1ips-Duphar) was injected intravenously.
Scanning was carried out b8 hours later on a Picker
Magnascanner or a $elo Superscanner D.S.7. The patients
received laxatives routinely, but if a doubtful area was
seen on the abdominal scan, the examination was repeated
2 b hours later after further laxatives. The scans were
reported by two independent observers. On some occasions
whole body scanning was not routinely performed, scans
being limited to the neck and chest. If an abdominal scan
was not performed in a patient with confirmed disease in
the abdomen, the patient was excluded from the study even
if the disease was present above the diaphragm. This has
possibly led to a slightly higher proportion of lesions above
the diaphragm being studied than would have been the case
had whole-body scanning been routinely performed.
Tumour concentration of ^Ga seen on scanning was
qualitatively assessed on a four level scale, using the
radioactivity 'level of the liver as a reference point. Thus
tumour uptake wa s : -
0. Not imaged.
L. (Low) Imaged, but only minimally,
6 7
the level of 'Ga uptake
being less than that, of
the liver.
M. (Moderate) Imaged, the level of ^ G a
uptake being moderate and
equivalent to that of the
1 ive r .
H (High) Imaged, and the level of &7Ga
uptake was high being greater
than that of the liver. (See
Figure 3 • 1) •
We found this classification satisfactory, virtually
all the lesions falling easily into one of the categories.
The category of each lesion was then correlated with its
histology and anatomical site. The histology was reviewed
by the Department of Pathology, Royal Marsden Hospital,
(Professor N. Gowing) and reported according to the Rye
modification of the classification of Lukes and Butler (1366).
Patients were categorized according to the level of
&7Ga uptake and this was correlated with the stage of
the disease, remission length and survival.
The presence of disease was determined by clinical
examination, radiology (including lymphography), isotope
and ultrasound techniques, pathology, biopsy and, in many cases,
laparotomy.
The patients were staged according to the system introduced
at Ann Arbor (Carbone et al 1972). Patients who relapsed were
re-staged. The length of remission following treatment was then
determined. There were two groups of patients. The first group
consisted of previously untreated patients with Hodgkin's disease
who were scanned on presentation. The second group consisted of
patients who had received treatment and who were scanned on relap
If a patient had more than one involved area, and these areas
had different levels of *^Ga uptake, then the patient was
O = no uptake
(glands in neck)
V
M = moderate uptake
m
L = low uptake
H= high uptake
categorised according to the lesion showing the maximum
uptake.
RESULTS
In all, 89 patients with Hodgkin's disease were studied.
These patients had a total of 2M anatomical sites involved
with Hodgkin's disease, giving an overall percentage of
positive scans of 62%. This percentage of positive scans is
lower than most other reported series, and is due to our
method of subdivision of anatomical sites. Host series have
grouped right and left lymphatic groups together, for example,
neck, axillae, and supraclavicular regions. It was decided
to separate these into right and left regions since both
- : j — - r _ ? 1— : i j u li ~ J ~ ~ I ~ -J : .— ^ U..+-
^ l u t- ^ kj 1 a may u a iiivcivou vy 1 111 11 vj u is 1 n o a t o t a j ^ ? u u l
the scan may only show uptake on one side. Separating the
regions lowers the scanning success rate when compared with
other series where regions rather than sites were examined.
fi 1
Table 3-1 shows the Ga uptake characteristics for all
the diseased areas grouped into the four histological
sub-classifications. Only a very small percentage of lesions
of "lymphocyte predominant" histology concentrated ^Ga
sufficiently to be imaged. There is a c,l ear improvement in
the ability to image the "nodular sclerosis", "mixed
cellularity", and "lymphocyte depleted" groups, but the
number of patients in the "lymphocyte predominant" group is
small and the apparent difference in imaging proper" ties,
although suggestive, is not statistically significant.
jLEl





































































LE 1. The intensity of Gallium 67 uptake or complete absence of uptake at each anatomical site of




Figures 3• 1 ~6 show the ^Ga imaging characteristics
at different anatomical sites. It can be seen that the site
of a lesion is an important factor in its imaging properties.
The mediastinum and lung are the disease areas most successfully
scanned giving 88% and 76% positive scans respectively.
Disease in both sides of the neck and the left supraclavicular
region was detected by 67ga jn approximately 60% of all cases.
Demonstration of disease in the right supraclavicular region,
the axillae and the abdomen was less successful, approximately
k0% of the known disease sites being positive.
The patients were then divided into two groups, the first,
group being previously untreated patients who were scanned on
presentation, and the second group being a treated group who were
Scanned on relapse. (This was done in order to ascertain whether
prior treatment affected imaging properties). The results of
scanning the neck and supraclavicular regions could not be
examined in this way because of the small numbers of patients
relapsingpin this areas. The 67Ga uptake at the remaining sites
was then reviewed. Detection of disease in the mediastinum showed
no significant change. The abdominal nodes and the axillae showed
a 30% increase in lesions imaged in treated patients while in the
lung there was a 30% decrease in lesions imaged. Possible reasons
for this are discussed later. When the disease areas are
sub-divided into their various histologies, it can be seen that the
"lymphocyte predominant" histology images poorly whichever area is
scanned, and the "lymphocyte depleted"histology tends to image





































67,Levels of u'Ga uptake related to known site of
sease. Anatomical sites tabulated are neck (right & left),
praclavicular regions (right & left), axillae, mediastinum
ncluding hilar regions), lung, para-aortic and pelvic. Tne
st five regions have eacn been sub-divided into previous
eated and untreated groups. Tne levels of u' G a uptake used
e described in detail in the methods section (p. pj)* briefly
ey are: 0 = no uptake; L = Low (uptake less than liver);
= Moderate (uptake equivalent to liver uptake); H = Hign
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Several other disease areas were also reviewed including
the gut, bone, inguinal and infraclavicular nodes, but
the number of patients so examined was too low to give any
statistically valid information. The spleen was not studied
because of difficulties in distinguishing between physiological
and pathological uptake of ^Ga.
The size of a mass of Hodgkin's disease might be thought
to be important in determining whether or not that mass will
image. Obviously, there is a lower limit beyond which disease
is undetectable due to limitations of the technique. On
investigating this possibility, we found great difficulties
in estimating the size of involved disease areas from an
analysis of the clinical notes because of the variations in
methods of rennrtinn or ahsenre of relevant records. After
attempting to relate the level of ^ G a uptake to size of
tumour mass using several different methods, no firm
conclusions were reached. This aspect will be discussed
later. Figure 3-7 is a graph plotting the stage of the
disease against the level of ^Ga uptai-e in each patient.
Although there is no clear-cut correlation beteen stage of
disease and level of uptake, there is a tendency for patients
with Stage 1 disease to fail to image (7/13)- It was found
that 8 1 % of all high uptakes were found in patients with
widespread disease of Stage HE or greater as compared to
kB% with moderate uptake, 6 0 % with minimal uptake and 38%
with no uptake.
Results relating" Ga uptake levels to the length of
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Fig. 3.7
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Figure 3-8 shows the cumulative percentage remission
rate of previously untreated patients with Hodgkin's disease
for each level of 87Ga uptake. Followup of the patients was
carried out for up to two years after the initial remission
was attained. There is a difference between the patients whose
lesions showed either no 87ga uptake or low ^7ca uptake, and those
showing moderate or high &7Ga uptake. None of the patients in the
former group have relapsed. There is also a difference in the group
showing moderate 87Qa uptake compared to the high &7Ga uptake group
in that the moderate group appear to be doing better than the
high uptake group at 6 months although by one year this difference
is less significant.
A study of the remission lengths of those patients who were
scanned on relapse is less informative from a clinical point of view
because some of the patients in this group have relapsed more than once.
The data has been presented in the form of a flowchart (Figure 3-9)
and again suggests that patients with a high level of &7Ga uptake had
shorter remissions than those with a low level of ^7Ga uptake or no
uptake.
Table 3-2 shows all patients who were scanned during the terminal
phases of their disease. Apart from one Stage 11E patient, all stages
were either 111E or IV. The patients are grouped according to the
level of 87ga uptake. The previous number of relapses before the scan
and the lengths of remission following treatment after the scan are
given. NR indicates no further remissions. It can be seen that most















































NR - No remission
Dd - Deceased
—* - Still in remission






















































These patients with high uptake had short survivals, most
less than h months. The few patients with absent and minimal
^ 1 Ga uptake achieved remission before death. The patient with




Most studies of Ga-citrate scanning in malignant disease
have concentrated on scanning success rates in various types
of tumour. There have been many reports assessing the
clinical status of ^Ga-citrate scanning in the management of
Hodgkin's disease. The earliest reports (Kay and McCready
1372; Turner eL a'i 1372) reported tiiel 73 % of region S
subsequently shown to be involved with Hodgkin's disease
could be imaged on scanning. The largest report has been
from the "Co-operative Group to Study Localization of
Radiopharmaceuticals" sponsored by the Oak Ridge Associated
Universities (johnson et ai 1975). They studied 151 patients
with Hodgkin's disease, finding that an overall 73% of proven
disease sites were positive on scanring. The percentage of
positive scans was highest in the neck and chest, and lowest
in the abdominal and inguinal node regions. They also found
that "scan detectability" of a lesion was not related to its
size or to the presence of systemic symptoms.
It has been apparent for some time that there is a
considerable variation in the visual Level of ^Ga uptake
seen on scans iri comparably sized lesions of the same
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histology. Little attention has been paid to this variation
in uptake, but the results of this retrospective study indicate
that there may be some clinical significance in this phenomenon
Nash et al (1973) studied a series of colonic and rectal
carcinomas and found some correlation of ^Ga uptake with the
degree of differentiation of the tumour, the poorly differen¬
tiated tumours taking up more ^Ga than the well-differentiated
tumours. It is possible that within each tumour group there
is a range of uptake levels which might reflect the degree of
malignancy. However, it is also clear that other factors are
involved in the process of tumour imaging. Several workers
have looked at ^ Ga uptake and histological sub-classification
of Hodgkin's disease without coming to any firm conclusions,
suffering from the same deficiencies as this study, namely,
that of low numbers of patients. (Kay & McCready 1972;
Johnson et all 1975).
Bearing In mind the low numbers of patients studied,
it was rare to image a mass of lymph nodes of "lymphocyte
predominant" histology. Lesions of "nodular sclerosis"
or "mixed cellularity" gave an average of 60% positive scans.
"Lymphocyte depleted" lesions were very successfully scanned,
but again, the number of patients in this group is small.
The extremely good results from scanning of the lung and
mediastinum confirm results from other centres. One cause of
this may be related to low background activity in the chest,
although this cannot be the whole answer, since background
activity in the axilla is low, and scanning results in this
area are poor.
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Figure 3-7 shows no definite correlation between
intensity of ^Ga uptake and stage of disease. However,
7 out of 13 patients who had no ^Ga uptake had Stage 1A
disease. It might be felt that these patients were likely
to have small neck lymph nodes, which would be difficult to
image from the point of view of size. Individual assessment
of the reported size of the glands did not confirm this, there
being quite a range of sizes from large matted masses of
lymph nodes to nodes 1 - 1.5 cms in diameter. It can also be
seen that those patients with "B" symptoms tended to give more
positive scans than those patients who were symptom-free.
It was a clinical impression that the very high levels
of uptake of ^Ga tended to occur in patients who were nearing
death after having received a variety of treatments. This
impression was strengthened by the finding that of 10 patients
who were scanned shortly before death, 8 had scans showing a
high level of ^Ga uptake and 2 had scans showing a moderate
level. No patients who died had low levels or no ^Ga uptake.
^ 7
In order to assess whether the level of Ga uptake relative
to the liver could be prognostically significant, it is
essential to assess separately patients who have not received
previous treatment and those who have. The results for the
former group are shown in Figure 3-8. This figure, although
being produced by standard actuarial methods (modified
Wilcoxon test) must be interpreted with caution. There is a
difference between the remission lengths of patients showing
rio uptake and low uptake and the groups showing moderate and
high uptake, the low and absent uptake groups having longer
remissions. The difference between the moderate uptake group
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and the high uptake group is only slight except at the
initial period of remission.
A flow-chart was constructed (Figure 3-9) of the
remission lengths of relapsed patients, but less prognostic
significance can be attached to it since this group
comprises patients who have relapsed a variable number of
times. However, this again suggests that heavy uptake of
^Ga indicates a bad prognosis, since nearly all patients
with heavy uptake had either short remissions or failed to
r em i t .
This is the first report, investigating this aspect of
uptake of tumour imaging radiopharmaceuticals in Hodgkin's
disease. Cheguillaume et al (197M found similar results
5 7 .
investigating co-iaDeiiea Dieomyc in up la n.e in care i n cm a
of the bronchus. They measured tumour: background
radioactivity ratios by means of a computer linked
gamma-camera ("Intertechnique") and found a correlation
between level of uptake and survival, patients with the
"hottest" lesions surviving the shortest time.
These results suggest that patients who have lesions
S 7
taking up Ga avidly may be in a more aggressive phase of
their illness or have a more aggressive disease than those
whose lesions have visually low levels of ^Ga uptake or
fail to visualize.
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3 -2 • SEMINOMA OF THE TESTIS
This section was published in the British Medical Journal, 1,1118-1121 (1976)
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INTRODUCTION
The development of a satisfactory tumour localizing agent for
the testicular tumours would be of considerable value from the
point of view of choice of therapy, localization for external
radiation and monitoring the response of the disease to treatment.
In seminomas, disease localization is of importance since the
tumour is exceedingly sensitive to radiation, and sites which are
usually vulnerable to radiation damage such as liver and lungs,
can be irradiated to tumouricidal dose levels without prohibitive
normal tissue damage. Thus, widespread disease is not necessarily
incompatible with cure. In testicular teratomas there is the
added problem of staging which is particularly relevant to a
combined irradiation-chemotherapy approach for disease which has
spread to the lungs and where it is important to exclude liver
involvement.
The use of the tumour imaging agent Gallium-citrate
(^Ga-ci trate) in the whole-body scanning of patients with
testicular tumours, has been assessed from 1972 onwards.
METHODS
2-3mCi of ^Ga-citrate, obtained commercially from Phi 1ips-Duphar,
was injected intravenously and ^8 hours later the patients were
scanned on a Selo Superscanner D.S.7- Bowel laxatives were routinely
used prior to scanning, but if any suspicious area of activity
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was seen in the abdomen, re-scanning 2b hours later was performed.
The tumours were classified in the Department of Pathology
(Professor N. Gowing), Royal Marsden Hospital according to the
classification put forward by the Testicular Tumour Panel and
Registry (Collins and Pugh 196k).
RESULTS
23 patients with pure seminoma were scanned and received a total
of 39 scans (Table 3-3). Of 15 scans performed at times when seminoma
was subsequently confirmed to have been present by other methods or
by response to treatment, 13 were positive in every disease site. There
was one false negative scan occuring in a patient with small, but
involved external iliac lymph nodes, which had been diagnosed on
lymphography. One patient must be classified as a "partial" false
negative. He had relapsed with bilateral hilar deposits with, in
addition, one deposit in the right upper zone and another peripherally
in the left lower zone. The Gallium scan was clearly positive in the
right hilar and right upper zone deposits, but was negative for
the left hilar and left lower zone deposits. The remaining 2scans
were performed on patients who were disease-free and were negative.
11 patients with a testicular teratoma were, each scanned once and
of nine who had disseminated disease with sizeable tumour deposits,
only 2 patients showed light uptake in the disease areas. The other
























8 patients with combined seminoma/teratoma tumours were studied.
These eight patients between them received 16 scans, one patient being
scanned seven times (see table 3>5). Of 3 scans which were negative,
no tumour was found with other investigations and this was confirmed
by the patient continuing in remission clinically. Tumour masses were
present at the time of the 13 other scans, and of these, five were
performed on patients who had a tumour which was histologically
thought to be, and clinically behaved like, a pure seminoma. These
scans were positive in all disease areas. 2 patients subsequently
developed teratomas, but unfortunately only one was rescanned. This
one patient had a mediastinal tumour, which previously had imaged very
well indeed with ^^Ga-citrate, but now could no longer be seen on
scanning. Five patients with known combined tumours failed to respond
to conventional treatment for seminoma and developed large masses of
teratoma which also failed to image with ^^Ga-citrate.
We scanned one patient with a mixed teratoma-choriocarcinoma
probably of mediastinal origin, and this tumour did image clearly
with ^^Ga-citrate.
Two cases in the series should be discussed in more detail, in
order to illustrate the value of Gallium scanning in seminoma of the
testis.
Case 1. (See figure 3.11-13)
Patient Z.J. was found to have extensive intra-abdominal
seminoma in 1969 for which he received radiotherapy. He relapsed in
Table3-5
Combinedtumours(Setino a/teratoma).















1972 with deposits of seminoma in the right neck, para-aortic region,
and prostate gland.
Chemotherapy was restarted and the patient went into complete
remission until October of 197^ when he suffered from severe abdominal
pain. From November of the previous year, ^Ga-citrate scans had been
performed at regular intervals as a follow-up procedure. An abnormal
£ ~j
area of Ga uptake was noted five months prior to the onset of
symptoms, but at that time, because of lack of corroborative evidence,
no action was taken (Figure 3- 11-12). A scan performed at the'onset
of his symptoms showed that the mass had enlarged in size (Figure 3-13).
At operation an S cm. mass of tumour below the liver was found. No
other investigation prior to laparotomy had indicated the presence of
disease. The patient was put on chemotherapy and the mass was
irradiated. He remained well until April of this year when a further
area of abnormal uptake was noted in the left upper abdomen (Figure 3-1^).
Case 2
This 37 year old patient had an orcli i dectomy for seminoma in the
summer of 197?-. There was no evidence oJ" a combined tumour at that time.
He was referred to the Royal Marsden Hospital in 1973 after relapsing in
the mediastinum and was treated with radiotherapy. A Gallium scan was
strongly positive in the mediastinum (Figure 3-15). He responded to
treatment and the scan returned to normal. However, in 197^, he developed
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a lover mediastinal mass which did not respond to treatment. This large
mass failed to image with ^Ga~citrate. He died from widespread deposits
of teratoma. A tumour which was previously known to take up ^Ga no
longer did so, suggesting that the character of the tumour had changed.
Case 3
A h~] year old man presented with a tumour in the left testis in 1973-
In September, 197*1, he was referred to us complaining of backache and
with evidence of extensive recurrent disease. A malignant teratoma was
initially diagnosed, but, on review, the appearances were more
suggestive of seminoma. There was radiological evidence of collapse
of the 9th and 12th dorsal vertebrae and the first three lumbar vertebrae-
There were also metastases in the right 10th and the left 5th and 6th
ribs. The scan taken in September, 197*1, (Figure 3-16A) showed increased
uptake in the head of the left humerus, the dorsal and lumbar spine
and in the ribs on both sides. There was also uptake in the ilium and
right pelvic lymph nodes. After chemotherapy and radiotherapy the
abnormal areas showing gallium uptake returned to normal. (Figure 3.16B).
At the time of writing the patient remained well controlled on
Cyclophosphamide.
DISCUSSION
Gallium scanning provides a convenient and safe means of whole
body screening in the management of patients with seminoma of the testis.
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Deposits of seminoma may arise in areas not easily accessible to
6 7
other diagnostic techniques. Difference in uptake of Ga in
tumour sub-groups has not been emphasized. For example, the uptake
characteristics of squamous cell carcinoma of the bronchus appear to be
no different to "oat cell" carcinoma (Van der Schoot, Groen and
de Jong 1972). The evidence presented in this report suggests that in
the testicular tumours, ^Ga may be mQre consistently taken up by
seminoma than by teratoma. In the followup of patients who are
suffering from what is presumed to be a pure seminoma, the change from a
positive scan to a negative scan together with a change in the clinical
course of the disease suggests that a teratoma may now dominate the
clinical picture.
Pinsky et al (1973) have recorded the largest series of scans
using ^Ga-citrate jn patients with testicular tumours. In this series
only abdominal scans were done, arid it was found that the method was
useful in assessing the spread of tumour to the abdominal lymph glands.
Embryonal carcinomas (anaplastic teratomas) tended to give positive
scans, but there were no patients in the series who had disseminated
seminomas and few who had more differentiated teratomas.
It is not known why seminomas, like lymphomas, have a high affinity
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for Ga. Swarzendruber, Nelson and Hayes (1973) performed electron
microscopic autoradiography on thymus and lymph node tissue of leukaemic
mice and found that &7Ga activity was predominantly in "lysosomal-1 ike"
granules within tissue macrophages. Inflammatory cells are known to have
a high level of lysosomal activity. Seminoma is a tumour clinically
characterized by a good response to treatment, and often histologically by
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the presence of granulomata and lymphocytic infiltration, whereas
teratoma of the testis is not generally characterized by either of
these features. This may contribute to the particularly good imaging
properties of seminoma.
The patient whose clinical details are summarized in
Figure 3.11-13 demonstrates the value of this technique in the
followup of patients with seminoma of the testis. The deposit of
seminoma below the right lobe of the liver was noted six months before
his clinical condition demanded exploratory laparotomy; the Gallium scan
was the only test which detected the tumour recurrence. In Figure 3-1^
a case history is given i11ustrating a difficult problem in the
management of patients with seminoma of the testis. A patient who has
been diagnosed as a pure seminoma and who then develops a recurrence in
a previously treated area or who has responded poorly to standard
treatment may have developed a teratoma and this diagnosis must be
carefully considered in the above situations. In this particular case,
a tumour which was previously known to take up ^7Ga no longer did so,
and this suggested that the character of the tumour had changed.
Figure 3-15 illustrates the value of Gallium scanning in the initial
staging of a patient and as a monitor of the response to treatment.
In conclusion, this technique was found to be of great value in the
diagnosis and followup of patients with seminoma of the testis. The
apparent difference in imaging characteristics between seminoma and
teratoma requires confirmation, and if proven, may have some value in the
differential diagnosis of patients with combined tumours of the testis.
B
Fig. 3.11-12 -Case 1. Serial scans of
upper abdomen. (A) December
197.3. Normal liver image show¬
ing area where seminoma depo¬
sit later develops (arrowed).
(B) May 1974. Abnormal area
of ,;TGa uptake below right lobe
of liver. (C) October 1974.
Abnormal area has increased.
Laparotomy revealed recurrent
seminoma below right lobe of
liver. (1)) April 1975. Further
recurrence in upper abdomen









































































Tig3.16—Case.(A)Beforetreatm nt fordisseminatedseminoma.In¬ creaseduptakeathe dofl f humerusandidorsallu b r spine,leftribsightlower ileum,andrightpelviclymp nodes.Thereisalsouptakeifaece inproximalc lon,whichdisa peared onrescanningafterlax tiv .B■ Afterchemotherapyandr dio¬ therapyseabnormalr asof ,i7Gauptakehavereturn dtonormal. Again,thereisfaecaluptakint e proximalcolon.
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J». MECHANISMS OF UPTAKE OF 67Ga INTO TUMOURS
1. GENERAL INTRODUCTION
This section comprised part of an article published in
British Journal of Radiology, bQ, 520-531 (July 1975)
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MECHANISM OF UPTAKE
The mechanism of uptake of tumour-loca1izing agents
is an intriguing and as yet, unsolved problem. Its
elucidation will not only rationalize interpretation of
clinical data, but may throw more light on the biology
of tumours as a whole.
Most research on the mechanism of uptake has been
67
done on Ga-citrate. It has been shown that Ga given
as ^Ga-citrate intravenously is bound to plasma protein
(Gunasekera, King and Lavender, 1972), predominantly in
the 3~globulin fraction and, within this, transferrin
appears to be an important carrier. In addition, a
haptoglobin peak can be seen on immuno-electrophoretic
autoradiography. However, 70 per cent of the scanning
dose in patients appeared to be loosely associated with
albumin and some globulins.
It is the mode.of uptake of the radionuclide into
the tumour which is proving difficult to explain on a
rational basis. Using light and electron microscopic
autoradiography, Swartzendruber, Nelson and
Hayes (1973), examined the cellular and sub-cellular
distribution of ^Ga in a variety of tissues in both
leukaemic and normal AKR mice. They found that ^Ga
localization in the normal mice occurred mainly in the
macrophages of 1ympho-reticular tissues, thymic epithelial
reticular cells, Kupffer cells, hepatic cells
* A.K.R. = Strain in-bred at Rockefeller Institute, 1935.
High leukaemic incidence.
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and cells of the proximal convoluted tubules of the kidney. in the
leukaemic mice heavy uptake occurred in the thymus and was related to
increased numbers of macrophages. The leukaemic cells, although taking
up 67Ga, were not so heavily labelled as the macrophages. The electron
microscopic autoradiographic pictures showed that 60% of the
intracellular 67Ga was associated with "lysosomal-1 ike" granules in
the cell cytoplasm. Others who have used biochemical cell
fractionation techniques have not supported this E-M autoradiographic
data. Becker et al (1972), performing ultracentrifugation of
homogenized normal mouse liver and Erhlich ascites tumour cells, found
that the ^Ga distribution within the various cell fractions was
greatest in the cytoplasmic supernatant fraction. In normal liver
cells, 33% of the ^Ga was in the cell cytoplasmic fraction, and
: ^ 4- u _ ^,— r _ 4. 11. 4-i— x.— . — c 1 x. m i • x. x. i _
III Clio ClOOIcOO CUIIIUUI OO I I O , C I IC pi UpU I L I OM I W (3D U I (JC I OCl I L , VCI y I I I t I C
radioactivity was found in the lysosomal fraction. These results have
been supported by Orii (1972). However, the proposition that 67Ga
localization occurred on or within 1ysosome-1ike granules was
supported by Haubold and Aulbert (1972) who found that using
ultracentrifugation of rat liver homogenate, the 6,500 - 9,000 G
sediment (the lysosomal fraction) contained 2b times the radioactivity
of the rest of the cell fractions. It is possible that variations in
the time interval between ^Ga-citrate injection and the fractionation
work would account for these differences.
The thesis that 67Ga is taken up by the 1ysosomal-rich
phagocytic cells of the reticuloendothelial system is an
attractive one. Recruitment of macrophages is known
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to occur in certain growing animal tumours (Met calf,
Ishidate and Brumby, 1967), and the idea of ^Ga
accumulation within a tumour occurring as a result of the
presence of macrophages within the tumour substance would
be of immense significance both clinically and from the
research point of view. Research on this aspect will
be described in a later section.
Others have suggested that ^Ga uptake may be related
to the rate of cellular proliferation. Using an ascitic
Pi asmacytoma (J.B.-l) and normal bone marrow cells in
Balb/C strain of mice, Bichel and Hansen (1972) showed
that in the rapid growth phase of the ascitic tumour,
there was a higher intracellular ^ G a uptake than in the
tumour's plateau growth phase. Furthermore, normal mouse
marrow made hyperplastic by prior bleeding of the mice took
up ^Ga more than hypoplastic marrow cells. However, it
must be said that although ^Ga uptake may be related
to the rate of cellular proliferation in the mouse
Pi asmacytoma and normal mouse marrow, it cannot be assumed
to be true for other types of normal or malignant tissues.
Hammersley and Taylor (197M have suggested that although
there is some form of relationship between uptake of
^Ga and the rate of DNA synthesis, the uptake of the
radionuclide is not simply related to the rate of DNA
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synthesis per se. They examined two mouse tumours in
detail , the Hard i ng-Passey (HP) melanoma and the
ADJ/PC6 plasma cell tumour. Three H-P melanomas of
different sizes were examined. In the smallest tumour,
61
there was a negative correlation between Ga uptake
and the rate of DMA synthesis, but in the larger two
tumours examined, there was a positive correlation.
These tumours were treated with radiation or cyclo¬
phosphamide, thus considerably reducing the rate of DNA
61
synthesis. There was, however, no decrease in the Ga
uptake. Indeed, in two ADJ/PC6 tumours, there was
increased uptake.
tl i_ ? — j— i— _« _ r i. _ j ? l. _ j • _
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this thesis has been approached from three angles. Firstly,
the macrophage uptake theory has been investigated;
secondly, the contribution of vascular permeability to
^ 7
tumour uptake of Ga has been investigated; thirdly,
research into the similiarities and differences between
67 k5the behaviour of Ga and Ca is described. One of the
great impediments to rationalization of cancer
chemotherapeutic regimes in humans is the sparsity of
suitable methods of measuring tumour response to treatment.
We are limited to observing whether a tumour gets bigger
or smaller, which often takes a long time to show, and to
measuring certain tumour products in the blood, such as
S3
ectopic hormones. Furthermore, it might be possible
improve the specificity of tumour localizing agents
the uptake mechanism were understood.
100
b.2 THE CONCENTRATION OF 67Ga and **5Ca IN THE LACTATING
MAMMARY GLAND AND ITS RELEVANCE TO THE TUMOUR UPTAKE
OF 67Ga-CITRATE
This section was published in Cancer Research, 3o_, b52-^57
(February, 1976)
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i NTRODUCT I ON
The detection of malignant tumours by whole-body
scanning after the injection of a radiopharmaceutical
which has the property of localizing within a tumour is
an attractive diagnostic method. However, this technique
is in its early stages of development and, in order to
improve tumour imaging, higher tumour : background
radioactivity ratios must be achieved. To this end,
the study of the mechanisms of tumour uptake and retention
of these agents and their systemic metabolism may lead to
improvements in imaging.
It is becoming clear that the phenomenon of tumour
uptake of radionuclides is not restricted to one or two
substances
^ but is a far more general phenomenon, embracing
a wide variety of radiopharmaceuticals. One of the commonest
in clinical use is ^Ga-cit rate which concentrates in a
variety of tumours. It is not a tumour-specific agent, and
it will concentrate within abscesses and other infective
processes, and also in certain granulomatous diseases such
as sarcoidosis. Physiologically, it is taken up in
significant amounts by the liver and spleen, small and
large intestine, and bone marrow. However, in addition,
striking physiological accumulation occurs within the
breasts of pregnant or postpartum women. It has also been
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observed in a young woman with Hodgkin's disease who
was neither pregnant nor postpartum. On this occasion,
the breast uptake was associated with lactation due to
hyperprolactinemia possibly caused by chlorpromazine or
by cytotoxic chemotherapy. (See Figure 5-1)
The mechanism by which ^Ga accumulates either in
tumours or in the lactating mammary gland is not fully
f) V
understood. Larson and Schall (8) measured the Ga
concentration in milk expressed from the breasts of one
of their patients and found that ^Ga was being secreted in
significant amounts in the milk. Fogh (5) also
measured the concentration of ^ ^ G a in breast milk and
found that is was approximately the same as the blood
^Ga activity, concluding that imaging of the breasts
was unlikely to be due to ^Ga accumulation within milk.
To obtain more information on the mode of uptake of
^^Ga in breast tissue and its possible relationship to the
mode of tumour uptake, ^Ga-citrate was compared to
4 5
Ca, a radionuclide that has been extensively studied in
relation to milk biochemistry.
METHODS
In the clinical study (Fig. 5-1), the patient was
given 2.5 mCi of ^Ga-citrate (Philips-Duphar N V ,
Netherlands) I . V . and was scanned '<8 hours later with a
Selo Superscanner D S 7•
Figure 5.i
This photoscan of the chest and upper abdomen of a young woman with
67
dgkin's disease shows increased 'Ga uptake at the left hilum, where there
=s a large involved node, and in the breasts. Normal uptake is also seen in
=e liver and bones. This patient had received quadruple chemotherapy with
=lorpromazine sedation 1 week prior to the scan. A scan taken before treat-
nt had started showed uptake in the left hilar region only. A further scan
-f'pek later showed that Ga uptake in the left hilar region had nearlv
turned to normal but that uptake in the breasts had further increased
^.sma prolactin levels were found to be raised during chemotherapy and return-
to normal after chemotherapy.
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ANIMAL STUDIES
The dogs, 2 lactating bitches and a dog bearing a
transmissible venereal tumour, received by i.v. injection 1mCi of
carrier-free ^Ga citrate plus 500 mCi of ^CaC^ (The
Radiochemical Centre, Amersham, Endland; specific activity,
10 to 40 mCi/mg). Blood and milk samples were collected at
intervals over a period of 100 hours. Biopsy samples of mammary
tissue were removed at 5 and 48 hours after the injection of the
radionuclides. Biopsy samples of tumour were removed at
approximately 24, 48 and 72 hours after injection of the radionuclides.
All biopsy material was placed on ice immediately after removal
cMiu diidiyZcu Willi ill 2 - iiOurS. Tliti diiinidi^ were
anaesthetized with halothane, following induction with thiopentone
and premedication with acetylpromazine.
The samples of mammary gland and tumour tissue were cut into
multiple small pieces which were weighed and assayed for ^Ga and
45
Ca. Other samples of gland and tumour were weighed and the
glandular tissue was rinsed in ice-cold 0.25m sucrose to remove any
adhering mil!'.. They were then homogenized in 0.25m sucrose and
subjected to subcellular fractionation by centrifugation at 400 x g
for 10 mins. to sediment nuclei + cell debris; at 6,000 x g for 15
mins. to sediment a heavy mitochondrial + lysosomal fraction; at
30,000 x g for 25 mins. to sediment the light mitochondrial +
lysosomal fraction, and at 105,000 x g for 60 mins. to sediment the
microsomal fraction and yield the soluble cytosol fraction. The
pellets were taken up in distilled water and assayed for protein and
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the marker enzymes, aryl.sulfatase (lysosomes) and succinate
dehydrogenase (mitochondria), using methods previously described
(Dodgsori, Spencer and Thomas, 1355; Pennington 1961 .)
& 7The radioactivity due to Ga in the tissue, tissue fractions,
plasma, and milk samples was assayed by Y - ray spectrometry in an
b5
automatic y - ray spectrometer. For the assay of Ca, the
samples were placed in glass liquid scintillation counting vials,
and 1m1 72% perchloric acid and 1 ml 30% (w/v) hydrogen peroxide
were added: the mixture was allowed to stand overnight at room
temperature. The samples were then heated at 70° for 2 to h hours
until a clear, norma 11y colour 1 ess solution was obtained (Seidel
r. /-I 1QT)1 ..I-.!- 1 1 -.----J r_.. tn
unv » i i , \ y f *- / j uiiu L.11V- v i u i j hoi c qiioi ouv_/icu i v_y i j \j
days to allow the ^Ga to decay. After storage 3 ml. of water and
10 ml. of an emulsion scintillant comprising 2 parts Tergitol TP9
(Union Carbide Co., Ltd., London, England) and 1 part 6% butyl-PBD
in toluene were added, and the vial was shaken well to mix the
b5
contents thoroughly. The resulting gel was assayed for Ca in an
automatic liquid scintillation spectrometer. The correction for
quenching was made by means of the external standard channels ratio
method.
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To determine the distribution of Ca and Ga between the protein
and non-protein components of the milk, samples of milk were layered
onto the top of a column of Sephadex G-75 (2.5 cm. in diameter and
10 cm. high) and eluted with 0.1 m Tris-HCL in 0.1^ mKCl buffer at
pH 7-^- Five-ml fractions were collected on an automatic fraction
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collector, and these fractions were assayed for ^Ca, ^^Ga and protein.
RESULTS
The relative concentrations of ^Ga and ^Ca in milk and plasma
over a period of 100 hr. following the injection of °^Ga-citrate and
i»5
Ca-chloride into a lactating dog are shown in Figure 5-2. As can be
seen from the data, there is a rapid fall in the plasma level of both
^Ga and ^Ca, while the concentrations of the 2 nuclides in the milk
rises to a peak within one hour and then falls relatively slowly. Thus,
there appears to be an early and substained concentration"! of both
^Ga and ^Ca in the milk, compared with the plasma. The
concentrations of both nuclides are very similiar in all the milk
Zj 5
samples examined, but the initial rate of clearance of Ca from the
& 7
plasma is more rapid than that of Ga.
Milk samples collected between and 7 hours after injection were
fractionated on Sephadex G~75> and similiar elution profiles were
observed for each of the samples examined. A typical elution profile
Z»5
is presented in Figure 5-3- This shows that almost all the Ca and
^Ga are eluted with milk proteins at the void volume of the column.
Small amounts of both nuclides, about 5% of the total activity, were
eluted in Fraction 5; this fraction corresponds to the elution peak of
^^CaCl^ and ^Ga-citrate under the experimental conditions used.
A 7 |i r
The subcellular distribution of Ga and Ca was studied in
samples of lactating mammary gland removed at 5 and ^8 hr. after
5J2i. 'he concentration of ^Ga and ^Ca in dog nlasma and milk following
Lmultaneous i.V. injections of ^Ga citrate and ^GaCl^.
void
FIGURE 5.3 .
Klution profiles of ^Ga (•-•)» and protein tV ▼) following fractionation
)g milk in Sephadex G-75» Protein concentration is expressed in arbitrary
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injection of the nuclides. The results of these studies are illustrated
in Figure 5-^ in which the relative specific activity of the nuclide
of the marker enzyme in each fraction is plotted against the percentage
present in that fraction. Relative specific activity is defined as
the percentage of the total ^Ga, ^Ca, or enzyme in the fraction;
using this method of presentation, the area of each rectangle on the
diagram is proportional to the percentage of the total activity
present in each fraction. From the data shown in Figure 5-5, it can
be seen that, at 5 hr. after injection, the relative specific activity
of Ca is more or less constant and equal to unity in each fraction,
with the exception of the heavy mitochondrial- 1ysosomal fraction.
However, with ^Ga, the relative specific activities in the mitochondrial-
lysosomal fractions and in the cytosol are greater than those in the
^ y
nuclear or microsomal fractions. At A8 hr. bfter injection, the Ga
Zj 5
and Ca activity was found predominantly in the lysosomal fraction.
At the early time interval 56% of the ^Ga and 53% of the ^Ca was
present in the cytosol and, at A8 hr., about *t0% of the total mammary
gland content of each nuclide was still present in this fraction. In
other studies a single sample of nonlactating human breast tissue was
6 7
subjected to subcellular fractionation and 61% of the total Ga was
found in the cytosol at 48 hr. after injection.
The subcellular distribution of Ga and Ca was also studied in
the transmissible venereal tumour at 80 hr. after the injection of the
nuclides, and the results are shown in Figure 5-6. In this tumour,
considerable amounts of ^Ca (61%) and ^Ga (40%) were found in the
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The subcellular distribution of ^Ga, ^Ga, and succinate dehydrogenase
) (mitochondrial marker enzyme) in breast tissue taken from dogs at 5
=^48 br. after i.v. injection of ^Ga citrate and ^^GaGl^. Relative
=uific activity is defined as the percentage of the total protein in that
Rtion. ncd, nuclei-cell debris faction; m, heavy mitochondrial lysosomal




















"The subcellular distribution of ^Ga, ^Ca, succinate dehydrogenase (SDH),
-iryl sulfatase in a dog tumour at 12 hr after i.v, injection of the nuclides.
;ions and abbreviations are as in Chart 3 legend. The relative specific
-ri.ty of all 4 parameters in the nuclei-cell debris fraction is close to
r, which probably reflect a high proportion of intact cells in this frac-
due to the difficulties of homogenizing this rather fibrous tumour.
FIGURE 5.6.
/'7 i r
Comparison of the concentrations of Oa and Ca in 12 samples of breast
tue taken from a dog 5 hr after i.v. injection of the nuclides. Correlation
'ficient, 0.948; 0.001.
113
nuclei-cell debris fraction. However, this tumour was very difficult
to homogenize and the presence of 53 to 75% of the marker enzymes
for mitochondria (succinate dehydrogenase) and lysosomes (aryl
sulfatase) in this fraction suggests that many of the tumour cells
remained unbroken after homogenization and that the ^5Ca and 67ga
were probably contained in these unbroken cells. Of the ^5ca and
6?Ga not contained in the nuclei-cell debris fraction, most of both
nuclides were recovered in the mitochondria 1 -1ysosoma1 fractions.
Tumour samples were obtained from the dog at 2k, 56, and 80 hr.
after simultaneous injection of ^Ca and ^Ga. The ^Ga concentration
in the tumour was similar at each of the 3 time intervals studied,
but the ^5ca concentration in the samples at 56 and 80 hr. was less
than one-half that in the sample removed at 2k hr. (Table 5-2). The
amount of 63(ja taken up ty the Iac.tating mammary gland at kb hr. was
similar to the amount taken up by the tumour (both were around
20% dose injected per kg.), but the amount of in the mammary
gland was less (7-7% dose injected per kg.) than the
67ca uptake at this time (see Tables 5-1 and 5.2).
The mammary gland and tumour biopsies were cut into 10 to 20
individual samples, and each sample was weighed and assayed for
^5Ca and 672a. At 5 hr. after injection, there was a very good
correlation (p=0.000l) between the uptake of 67Ga and ^Ca jn the
12 individual samples of mammary gland examined (Figure 5.7), but,
% ^Va/fc X Iff4
FIGURE 5.7.
Dmparison of the concentrations of ^Ga and ^Ca in 19 individual pieces of
tumour removed 56 hr after i.v. injection of the nuclides. Correlation
sicient, 0.190;p } 0.1.
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- 48 hr., no similiar correlation was found in 20 tissue samples.
if. C. ~i
A comparison of the concentrations of Ca and Ga in the
individual samples prepared from each tumour biopsy showed no
simple correlation between the uptake of ^Ca and that of ^'Ga
at any of the time intervals studies; the data for the tumour
sample removed at 56 hr. are shown in Figure 5-3.
DISCUSSION
This study has examined in more detail the phenomenon of
breast imaging occasionally observed when °'?Ga-c i t rate is used to
image malignant disease. The case history briefly described in
Finn r<^ F 1 •; hnuic fhaf" h rone t imanlnn n Arr iir haF An 1 \/ I r-i -»»-> 4-
— W . ^ WWUI ..WC. I I J ill K ' '"o1 ,u" ^
and postpartum women, but also occasionally in other patients.
We presumed that, in the case described, the hyperprolactinaemia
stimulating lactation had been caused by the administration of
chemotherapy which contained, among other drugs, ch1orpromazine.
These studes on the lactating bitch, which proved an ideal model
for collection of blood and adequate quantities of milk, have shown
^1 ^7
that Ga accumulates in both milk and mammary tissue. The Ga
concentration in milk relative to plasma increases steadily with time,
67 45
and Ga, like Ca, is present in milk firmly bound to protein. The
concentration of ^Ga in mammary gland tissue is about one-half that
found in milk at 5 hr. after injection but, by 48 hr., the
concentrations present in milk and in glandular tissues are
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approximately equal. it seems, therefore, that it is the uptake
of 67Ga in both glandular tissue and milk that causes the
visualization of the breasts when scanning is performed at 24 to
48 hr. after ^Ga administration.
G1
The mammary gland biopsies taken at b and 48 hr. after - 'Ga
citrate administration showed little difference in the subcellular
distribution (figure 5-3) of the 2 nuclides and, at 48 hr., the
highest relative specific activity of tjoth 67q3 anc| 45q3 was founcj
in the lysosomes.
Similarities in the metabolic behaviour of gallium and calcium
have been suggested by Anghileri (1972, 1974) from studies of the
subcellular distribution of ^Ga ancj 45ga ;n various experimental
tumours and from the displacement of ^7ga from phospholipid and
other complexes by excess calcium. The subcellular distribution
of ^7ga ancj 4 -^Ca in the mammary tissue samples examined here appear
at first sight to be in broad agreement with the observations of
Anghileri. However, the apparent similarities in the subcellular
distribution of the 2 nuclides must be interpreted with caution.
The subcellular fractionation techniques used by Anghileri
and those used in this work, do not produce clear separation between
micochondria and lysosomes. Autoradiographic and other studies
(D.M. Taylor, unpublished observations) suggest that 6/Ga is
predominantly associated with lysosomal structures, whereas calcium
is known to be associated extensively with mitochondria (Vasinqton
and Murphy 1962). Thus, although most of- the total cellular ^Ga
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and Ca was found in the mitochondrial and lysosomal fractions,
the possibility that most of the ^Ga was associated with the
lysosomes and most of the ^5Ca with the mitochondria cannot be
excluded. Perhaps the strongest evidence for an interrelationship
between calcium and gallium metabolism comes from the observations
regarding milk that showed similar activities of the 2 nuclides,
both being wholly associated with the milk proteins.
The lactating mammary gland, although metabolica11y highjy
active, is not a rapidly dividing tissue. It is stimulated by
the hormone prolactin to produce a variety of proteins, the
principle one of which is casein. Calcium metabolism has been
studied quite extensively in lactation, especially in domestic
animal's. There appears to be a common pattern of distribution of
minerals in different species between colloidal and soluble phases.
For example,-two-thirds of calcium in cow's milk is in the colloidal
phase as calcium caseinate, phosphate and citrate; one-third is
present in the soluble phase as "citrate acid-bound" and ionic
calcium (Kon and Cowie, 1961) . In this way, normal osmotic
equilibrium is maintained in the face of increasing calcium
concentration. Calcium is known to be present in the protein membrane
of fat globules , and ^Ga concentration may involve a similar
A 7 | r
mechanism. We found that concentrations of Ga and Ca in milk
were very similar and that there was a positive correlation between
the uptake of b^Ga and ^5pa in the multiple pieces of mammary tissue
examined at5 hr. after injection, although, by kQ hr., this
I I o
correlation no longer existed. Plasma concentrations of the 2 nuclides
were also comparable. On f rac.t ionat ion of the milk, the ^Ga
was found to be uniformly distributed throughout the protein fractions,
as is calcium. The production of protein by the mammary gland allows
cations such as Ca and, presumably Ga to be chelated, thereby
enabling concentration of minerals to occur while maintaining the
osmotic equilibrium.
/ T7 | f"
It was felt that the concentrating mechanism of Ga and 5Ca in
malignant tumours might be similiar to that in the lactating mammary
gland, concentration being allowed to occur by the continual
production of binding proteins by the tumour. However, it was not
possible to show this in a dog transmissible venereal tumour. This is
a spontaneously occurring neoplasm that can be transmitted at coitus
and that causes lesions of the penis and vagina. It can be transplanted
subcutaneous 1y in dogs, without any form of immunosupression, where
it forms large nodules that can be conveniently biopsied. it
occasionally metastasizes under these circumstances, but both
naturally occurring and transplanted tumours eventually undergo
67
spontaneous remission. It was found that Ga concentrated very well
kSin the tumour, but that Ca was present in very small amounts. The
^Ga concentration in the tumours was constant over 3 days, but the
^5
'Ca concentration dropped after the first day. Furthermore, there
67 hS
was no correlation between Ga and Ca uptake in multiple small
tumour pieces.
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The amounts of taken up by this tumour and the lactating
mammary gland were similar at ^8 hr. In the mammary gland, although
there was less taken up than 67q3> rate Df dispersion from
the gland was similar. In the tumour, however, &7Ga was retained
longer than ^^Ca.
These results indicate that, in the lactating mammary gland,
67Ga and ^Ca may follow broadly similar metabolic pathways, but
the mechanism of uptake of ^7Ga and ^5ca into tumours does not appear
to be simi1 ar.
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^.3 Macrophages and the Uptake of ^Ga in cumours
This section comprised part of a paper given at the
111rd European Congress of Radiology, Edinburgh, 1975-




The association of ^Ga with "]ysosoma]-1 ike" structures
was first reported by Swartzendruber, Nelson and Hayes (1973)
and subsequent reports from various centres have confirmed
this observation in a number of other tumours. This group
£ -Jfound that Ga localization in normal mice occurred mainly
in the macrophages of 1ympho-reticu1ar tissues, thymic
epithelial reticular cells, Kuppfer cells, hepatic cells
and cells of the proximal convoluted tubules of the kidney.
In the leukaernic mice heavy uptake occurred in the thymus
and was related to increased numbers of macrophages.
The thesis that b^Ga is taken up by the lysosomal rich
phagocytic cells of the reticulo-endothelia 1 system is an
attractive one. Recruitment of macrophages is known to
occur in certain growing animal tumours (Metcalf, Ishidate
and Brumby, 1367) and the idea of ^Ga accumulation within
a tumour occurring as a result of the presence of macrophages
within the tumour substance would be of immense significance
both clinically and from the research point of view.
The recent development of relatively simple techniques
has enabled the study of macrophage populations in tumours
(Evans and Alexander, 19/2). Using these techniques, it is
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possible to calculate the macrophage content of
transplantable tumours grown in experimental animals
and possibly human tumours, although this is proving more
difficult due to the fibrous stroma of many human cancers
(Gauci and Alexander, 1975).
The MC3 tumour ( a sarcoma induced by methylcholanthrene)
grows in both Hooded and August rats, but the size of the
tumours obtained 10 days after implantation varies
considerably. In view of the strong possibility that other
factors such as cell proliferation, interstitial fluid
volume and vascularity were influencing results, it was
decided that the only reasonably accurate comparison of
^Ga uptake would be to examine identical tumours in the
same animal strain where the only variable was macrophage
content. This opportunity presented itself in the form of
the HSBPA tumour, another chemica11y-induced sarcoma, which
after 25 passages exhibited a change in macrophage content
to around 50% , whereas earlier passages had a content of
around 5 ~ 10% macrophages. Animals carrying the tumour
transplanted at an earlier passage were then compared for




C hern i ca 1 1 y - i n du ced tumours (MC3 and HSBPA) were
transplanted into the hind limbs of two varieties of rats,
the Hooded rat and the August rat.
At a time -when the tumours had reached the size of some
3 ~10 G , ^ ^ G a citrate was injected intraperitoneal ly
Twenty-four to seventy-two hours later, the rats were
sacrificed and the tumour and the liver were dissected out
in toto and a nru scle biopsy was taken. The tumour, the
G1
liver and the muscle biopsy were assayed for Ga activity
by gamma-ray spectrophotometry in an automatic gamma-ray
spectrophotometer.
A small sample of the tumour was kept aside for
estimation of the tumour macrophage content. The sample
was trypsinised for half an hour (0.1G bovine pancreatic
trypsin in 100 mis. 0.9% saline with D.N.Aase added) in a
continually stirred flask. A drop of the cell suspension
thus obtained was pipetted onto a haemocytometer and the
total number of large cells vjere counted. The h a emoc y t ome t e r
was then incubated for ten minutes at 37® C and the number of
glass adherent cells were then counted, using phase contrast
microscopy. The number of these bells (macrophages) was then
12/)
expressed as a percentage of the total number of cells.
The MC3 tumour was grown in 4 Hooded rats and
A August rats. The HSBPA tumour was grown in 6 Hooded
rats. The HSN tumour, another chemica11y-Induced sarcoma,
was grown in 3 Hooded rats for the purposes of comparison.
This tumour became infected, but the results are also
shown with the HSBPA tumour. One of the HSN rats died as
a result of anaesthesia.
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RESULTS
The MC3 tumour grown in the hind legs of Hooded rats
has a low macrophage content of around 5%. On the other
hand, the same tumour when grown in the hind legs of the
August rat, has a macrophage content of beteen 30 - 50%,
depending on the passage. At the time of the study, the
macrophage content was around 50%. The results of the
k^Ga uptake in the MC3 tumour grown in Hooded rats and
August rats are shown in Fig. 5-8. The open circles show
the ^ ^ G a activity in the MC3 tumour expressed as %dose/Gm
wet tissue and the black circles show the ^Ga activity
expressed in the same way for the liver. There is a clear
difference in the tumour uptake of ^ ^ G a in the two different
species of rat, while the liver uptake remains constant.
6
There is almost three times as much 7 G a activity in the
high macrophage tumour as there is in the low macrophage
tumour. In this experiment, the tumour was weighed in toto,
and these results are shown in. Figure 5-9- As can be
seen, the tumours in the Hooded rats (the low macrophage
content group) in general reached a larger size and weight
than the tumours in the August rats (the high macrophage
content group). Other factors, such as vascularity and
interstitial fluid volume may have contributed to the
^ 1
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, Uptake of ^7qa in tumour (o) compared to 1iver (•) in the
. tumour (methy1cho 1 anthrene induced) grown in Hooded rats
August rats. There is a two-fold increase in ^'Ga uptake
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^' Ga uptake (relative specific activity) compared to wet
it of the MC3 tumour grown in August and Hooded rats. The
umour when grown in August rats is a smaller lighter tumour
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It was therefore decided to examine the ^Ga uptake in
the same tumour growing in the same species of animal at
times when the macrophage content of the HSBPA tumour
varied with the passage of the tumour. ^Ga uptake in
the HSBPA tumour grown in Hooded rats was compared between
tumours grown after 25 passages when the macrophage content
was 501, and tumours grown at an earlier passage when the
macrophage content was 5 ~ 10%. These results are shown
in Figure 5.10. No significant difference in ^ G a uptake
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Uptake of ^Ga (relative specific activity) in tumour (o)
liver (•) in the HSBPA tumour grown in Hooded rats. In the
columns, the HSBPA tumour has been grown in Hooded rats at
ssage when macrophages comprise lj0% of the cells within the
ur substance. In the middle columns, the HSBPA tumour grown
he Hooded rat is at an earlier passage and macrophages comprise
10% of the tumour substance. In the right columns, as a
arison, the HSN tumour (grown in Hooded Rats) with 2 macro-
—es, became infected. ^'Ga uptake is greater in this group,
—e is no difference in uptake in the HSBPA tumour grown in
—ed rats at the 2 different macrophage contents.
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DISCUSSION
In this study, no conclusive evidence was found to
support the suggestion that macrophages contributed
significantly to the uptake of ^Ga by malignant tumours,
using these direct methods.
67
The association of Ga with lysosomal structures has
been shown by Swartzendruber, Nelson and Hayes (1973) and
confirmed by Hammersley et al (1975), using sub-cellular
fractionation techniques. The maximum activity of the
nuclide is seen in the fraction containing the highest
c r*o r ! f ' r ar t- I 1 f \/ r\ f 1- h o l\/cr>comal rn a r 1/ o r pn 7\/mp ^ r \/ 1
^ Y> w w . • . w VJ w «. • « * w / w. . j ~ ~ W ... ~ - — / - — • / •
sulphatase.
In attempting to study the role of macrophages in the
6 7
uptake of Ga in tumours, indirect methods have also been
(S
used. If macrophages were involved in the uptake of Ga,
it might be expected that there 'would be a relationship
between the uptake of the nuclide and phagocytic activity
as measured by uptake of particulate matter. Hammersley
et al (1975) studied mice bearing human tumour xenografts
or transplanted murine tumours which were given ^Ga-citrate
9 9 m
and Ic sulphur colloid intravenously. No consistent
correlation was seen in the variety of tumours examined.
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In the studies described above, using the MC3 tumour
where the macrophage content when grown in the August rat
is about 8 times the macrophage content when grown in the
67
Hooded rat, the Ga uptake in the August rats is only about
threefold the uptake in the Hooded rats. This difference
in uptake is probably not significant, as the tumours in the
Hooded rats were larger, and larger tumours tend to take up
less nuclide than small tumours on a Idose/Gm basis. In
the HSBPA tumour grown in Hooded rats, no significant
difference in ^ G a uptake was seen in tumours with low
macrophage contents or high macrophage contents.
99m
These results confirm the observations with Tc
and suggest that macrophages do not play a major role in
£> 7
the uptake of Ga in tumours.
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^ 1h.h Gs uptake and Tumour Vascularity
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6 7
G a uptake and Tumour Vascularity
Int roduction
It is obvious that for any substance to concentrate
within a malignant tumour, the properties of the tumour
vasculature and blood-flow are of some importance in
determining uptake. It is the relative importance of
vascularity in the uptake mechanism which is difficult to
assess .
Tumour blood-vessels have formed a recent focus of
attention from the work of Folkman and others on tumour
angiogenic factor (Folkman 1971). The histological and
pharmacological characteristics have also been examined.
Neyazaki et al (1970) have described tumour blood vessels
as "sinusoidal blood canals consisting of a thin-layered
endothelial wall. Endothelial cells cf tumour vessels
had fenestrations, diaphragms and pores which are also
observed in the fenestrated type capillary in inflammation."
Their pharmacological characteristics have provided
apparently conflicting results although much of the
conflict may be due to differing techniques and tumour
types used. Zarielli, Fowler and Lucas (1976) have shown
that anaesthetics such as Nembutal and Urethane increase
13*»
relative perfusion of tumours as measured by uptake of
86 12 5
R b , and decreased uptake of I H.S.A. The response
to adrenaline differs from the response in the normal
vascular bed (Abrams 196*0.
Blood flow through tumours has been directly measured
by Gullino and Grantham (1961). These workers found a
greatly reduced blood-flow through tumours when compared
to normal tissue arid furthermore the blood-flow was
independent of tumour size and histology being a fairly
constant amount of 0.15 mls± .01/ng tumour.
To investigate the contribution of blood flow, tumour
i ntra-vascu1 ar volume and permeability in the uptake of
^
G a into tumours is obviously a major undertaking and the
experiments described below were undertaken as a pilot
exercise to assess whether any form of relationship of the
above factors with ^ ^ G a uptake could be found. it was
decided to investigate the permeability of tumour blood
vessels to ^ I H.S.A." and its relationship to ^Ga uptake.
'-H.S.A. = Human Serum Albumin
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METHODS
The Walker-256 carcinoma was implanted into the hind
legs of 6 Wistar rats.
^Ga-citrate (0.1 mis., of saline diluted
^Ga-citrate obtained from Philips-Duphar) and '^l-HSA
(0.5 mis of a standard solution of 5 m C i /1 rn 1 ) were
injected intravenously into the tail veins of the animals.
The animals were sacrificed at k5 minutes post-injection,
and the tumours were dissected out in-toto. The tumours
were then cut into multiple small pieces, weighed and
assayed for ^Ga and ^"*1 on an automatic gamma-
spectrometer using appropriate channels for ^^Ga and ^"*1.
An aliquot of the solutions injected was assayed as a
standard.
RESULTS
The results are expressed as % dose injected/gm.
tissue. Statistics were performed by standard Chi-squared
analysis.
Figure 5.11 shows the results of ^Ga uptake in
multiple pieces of Walker 256 carcinoma in 6 Wistar rats
1 2 5sacrificed b5 mins. after injection of I. H.S.A. and
^Ga-citrate. There is a highly significant positive
correlation of uptake of the two radionuclides in 5 of the
6 animals. (P> 0.01).
Comparative upt >' of 67Ga and 12*I.albumin
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albumin % dose/gm.
5.1 I
There Is a statistically significant correlation (fi^o.05)
•een k7ga uptake and ^1. labelled albumin in 5 of 6 Wlstan
at 45 minutes post-injection.
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DISCUSSION'
The results of these preliminary experiments suggest
that soon after injection of ^Ga citrate, the. i n t r a - t umou r
^ 7distribution of Ga closely resembles the distribution
12 5of I H.S.A. There was a strong positive correlation in
distribution of the two nuclides within the tumour at
1(5 minutes. Furthermore, the absolute amounts of the two
nuclides were similiar at around 0.3% dose injected/gm.
for the Walker-256 carcinoma. It is reasonable to suppose
6 7 67
therefore that protein-bound Ga, either as Ga-transferrin
or loosely bound to albumin or globulin, enters the tumour
interstitial fluid via fenestrations and pores in the
loose network of endothelial eel Is1which form the tumour
1 2 5
vasculature, in the same way as I H.S.A. Thereafter,
other factors must take over. This might be explained by
1 2 5
the 1 H.S.A. becoming evenliy dispersed throughout the
interstitial fluid of the tumour and. in contrast, the
^ ^
G a becoming attached to binding sites fairly rapidly and
/
7
thereby not dispersing evenly. It is known that Ga
activity is associated with viable tumour tissue, the necrotic
areas having low ^Ga uptake. In the Walker-256 carcinoma
67 12 5
much the same total amount of Ga and I H.S.A. as % dose
injected, was taken up at A5 minutes.
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The question as to whether tumour vascularity is a
major contributing factor to the tumour image obtained by
Gallium scanning must await further studies, in particular,
a measurement of total uptake of the two nuclides over a
series of time intervals.
It seems likely that once ^Ga has entered the tumour
interstitial fluid, secondary uptake mechanisms come into
play, allowing thereby the accumulation and retention of the
nuclide in a similar way to 1251 H.S.A. where Initial
permeation of the tumour vasculature is followed by
pinocytosis of the nuclide complex by the tumour cells
(Raimondi 1967)- in summary, therefore, tumour vascularity
plays a part in the uptake mechanism of ^Ga into tumours but




There can be no doubt that the technique of whole body
scanning using tumour imaging radiopharmaceuticals is
potentially one of the simplest and most accurate methods of
demonstrating the local site and distant spread of malignant
tumour. However, it must be obvious from this thesis that at
present, although relative simplicity of technique has been
achieved, we cannot yet consistently and reliably detect tumour
deposits less than 2 cm. in diameter. Occasions when present
radiopharmaceuticals and apparatus reveal disease not shown by other
means are few, but this should not detract from the important
advantage of ease of technique when compared to other diagnostic
methods.
From the survey of a substantial number of clinical reports,
it is concluded that no one tumour imaging agent is vastly superior
to another. There are striking similarities in the kinds of tumours
demonstrable by these agents and they can all exhibit uptake into
inflammatory exudates. (An explanation for this may be the presence
of the "fenestrated" capillary in neoplasms and inflammation.
This "leaky" cap:llary is also present in endocrine glands, choroid
h7
plexus and intestinal villi - regions where Ga uptake may be higher
than normal. Other areas of high nuclide uptake such as the liver,
spleen and bone marrow have sinusoidal vascular channels, consisting
of a discontinuous type of capillary with large pores and a defective
basement membrane).
67 Ga -citrate is probably the most widely used tumour imaging
1*11
agent. The main reason for this is that, for scanning, it has
very suitable physical properties and an acceptable radiation
risk for use in patients. The clinical scans obtained appear to
be better with ^Ga-citrate than with other agents, but there is
only limited comparative evidence to support this view. The
comparative study between ^ ^ In-bleomyc.in and Ga-citrate described
in this thesis is one of the few controlled studies reported in the
literature and one of the largest. It is an obvious point, but one
worth emphasizing, that in the detection of small differences, a
comparative trial of similar design to the one described is
essential. !n this trial, it was readily proven that ^Ga- ci trate
1 kl -u 111was more valuable than ln-bleomycin in the detection of lesions
above the diaphragm. One of the interesting points to come out of
this trial was that the detectable differences were not an
"al1-or-none" imaging difference, but one of degree. Very few lesions
imaged with one radiopharmaceutical and not the other. In the
comparative study of ^^Co-bleomycin with ^Ga-citrate, the disadvantage
of difficult radioactive waste disposal was greater than any
possible improvement in imaging quality.
In the subsequent clinical studies, by examining a specific
malignancy in depth an attempt was made to elucidate common factors
£> 7
for adequate tumour uptake of Ga. Hodgkin's disease, non-Hodgki'n 1 s
lymphoma and carcinoma of the bronchus are imaged well by a number
of radiopharmaceuticals, including Ga-citrate. It was found that
seminoma of the testis produced consistently excellent scans; tumour
1*»2
deposits measuring 1.5 cm. in diameter could be clearly imaged.
This malignancy, curable by modern radiotherapy, provided a clear
indication for Gallium scanning, since tumour deposits, not found
by other investigative techniques, were frequently found. On the
other hand, Gallium scans in Hodgkin's disease often recorded
disease sites which had been found by other techniques. There is
no good evidence of uptake of other radiopharmaceuticals in seminoma
of the testis since they have been infrequently scanned in reported
series. Seminoma deposits were invariably picked up by Gallium
scanning whereas teratoma deposits, although often being detectable,
v/ere not consistently detectable. One patient described, who had a
combined testicular tumour showed positive Gallium scans during the
seminoma phase of his illness and negative scans during the teratoma
phase, suggesting that the biological change from "seminoma-
predominance" to "teratoma predominance" had changed the properties
of uptake of radionuclides.
In the retrospective analysis of Gallium scans in Hodgkin's
disease, the main conclusion drawn from the many graphs and tables
presented, was that patients who were approaching the end of their
disease often showed marked uptake, of in tumour sites. The
possible relationship of level of initial uptake of 67ga to prognosis
is very suggestive and a prospective study would be the next obvious
step.
From the aspect of future development of this diagnostic
technique, one must consider carefully the aims in tumour diagnosis.
In most clinical series, the majority of cases are comprised of
large tumours which have been detected by other methods and then
scanned to see whether or not uptake occurs. In these cases,
presumably the aim of the scan is to differentiate between benign
and malignant tumours. However, it is clear that the tumour imaging
radionuclides are not specific for malignant lesions, and it is
likely to be difficult to improve this specificity for reasons to
be discussed later. Furthermore, the histological diagnosis of a
lesion will always in the end be decided by a histologist. Therefore,
there are two areas of clinical interest where research should be
channelled. The first area is in the detection of small tumour
deposits and the second is in the monitoring of the activity of
established malignant disease. It is unlikely that radioactive
tumour imaging agents will ever/ be used as screening tests for the
early diagnosis of malignant lesions because of the radiation hazards
involved, but the ability to detect small tumour metastases in the
investigation of the patient with histologically proven cancer would
obviously be valuable. This attempted goal must be viewed in the
light of recent advances in other diagnostic methods, such as
ultrasonography. This technique is highly competitive in certain areas,
particularly the abdomen, but in contrast to radionuclide tumour
imaging, ease of whole body screening is not a feature of ultrasonography
in its present state of development. In order to detect smaller
lesions by means of tumour imaging radionuclides one will need agents
which give more favourable tumour:backgfound ratios, whether this is
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achieved by increasing the concentration of the agent within the
tumour or by lowering the background activity-
It is proving difficult to account for the mechanism of
uptake, accumulation and retention of these nuclides on a simple
basis. It is likely that the permeability characteristics of
tumour blood vessels are a significant factor in ^Ga uptake, allowing
the radionuclide to come into contact with tumour cells after which
other accumulator mechanisms take over. The results obtained in the
Walker-256 carcinoma with 67Ga and 125| HSA would be consistent with
this idea.
These accumulation mechanisms may vary with the predominant
cell type in the tissue being studied. Merz et al (1974) have
shown that in thymus dependent lymphocytes, both unstimulated and
stimulated by PHA, °/Ga associated tenaciously with the plasma
membrane. On the other hand, in the lactating mammary gland
(section 4.1), similarities were found in the accumulation of
*5Ca and 67Ga in breast tissue. These similarities were not found
when tumour tissue was studied. The thesis that tumour macrophages
play a significant part in ^7ga uptake and retention in tumours was
not confirmed (Section 4.3).
An important need is to develop a reliable method of
monitoring the activity of malignant disease after treatment: we
have few methods of doing this apart from clinical examination and
radiography, both of which have their limitations. To achieve this
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purpose several obstacles must be overcome. Firstly, we need to
know the effect of treatment on the uptake of the agent and secondly
we must know as precisely as possible why these agents accumulate
in tumours. The third obstacle will be rather more difficult to
overcome. This is to produce a tumour imaging agent which is more
specific for malignant disease than any other available at present.
The reason for this difficulty is simply that there is no known
constant feature of malignant disease which is not at some time
observable in normal tissues.
However, there can be no doubt that the task is worth the
effort when one considers the few methods we have for the study of
the behaviour of tumours in humans. The study of radioactive
tumour imaging agents involved in some intrinsic and understood part
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